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Abstract  
A novel technology for the generation of light emitting somatic transgenic animals has been 
developed using lentiviral vectors where luciferase expression is transcriptionally regulated 
by tandem, synthetic, transcription factor binding elements. This allows signalling pathways 
in diseased organs to be monitored continually and consciously and in a non-invasive manner.  
I was able to confirm my hypothesis that long term somatic transgenesis could be achieved 
within the CNS after a single neonatal intracranial injection of the biosensors. No signs of 
activated microglia or astrogliosis from the injection or the vector expression was observed.  
I generated several lentiviral biosensors and this included an astrocyte specific biosensor 
GFAP.  
I established and validated a Hypoxic Ischemic Encephalopathy mouse model in outbred CD1 
mice. I applied somatic transgenic technology to the HIE mouse model to investigate whether 
it was possible to predict the severity of the disease in live mice. Unexpectedly, the luciferase 
expression from the four biosensors failed to correlate with the extent of brain infarct or the 
weight of the mice.  
To investigate this surprising results, I challenged the underlying assumption that GP64 
enveloped lentiviral vectors target GFAP positive astrocytes. Interestingly very few astrocyte 
positive cells were being targeted by the GP64 pseudotyped lentiviral vectors.  
As GFP expression from lentiviral vectors was limited and mainly situated around the injection 
site, I investigated the use of AAV delivery to the CNS. AAV8 vector generated strong and 
homogenous GFP expression. An AAV8 NFκB biosensor was made and injected intracranially 
to new-born mice. This showed substantially more stable luciferase expression compared 
with lentivirus vectors.  
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1 Introduction 
1.1 Gene transfer  
 
Viral vectors are derived from viruses, which are infectious particles which can introduce the 
viral genome into the host cell. Many viral vectors in the last couple of decades have been 
used for the purpose of gene transfer. Retroviruses consist of single-stranded RNA genome 
(7-11 kb) which is enveloped by a lipid-envelope particle (Kay et al. 2001). Vectors derived 
from retroviruses are advantageous as their genes are integrated within the host genome and 
are able to produce long term expression of the desired gene. This family of viruses consists 
of other members which have been used for gene therapy means, these include; lentiviruses, 
mammalian and avian C-type retroviruses and spumaviruses (Kay et al. 2001). Lentiviruses 
such as human immunodeficiency virus (HIV) have been shown to be effective tools for gene 
transfer to a wide range of cells which include post-mitotic cells (Naldini et al. 1996). This gene 
transfer vector will be discussed in greater detail.  
The other viral vector which will also be discussed in this chapter and has been widely used 
for gene transfer is Adeno-associated virus (AAV). AAV’s are human parvoviruses which 
require a helper adenovirus to produce the virus and therefore require it for replication. They 
were first discovered in 1965 as “virus like particles” in an adenovirus preparation, where they 
had been separated and identified from simian adenovirus type 15 (As- et al. 1965). This was 
followed on by the sequencing of the first AAV serotype, serotype 2 in 1980 (Lusby et al. 
1980). AAV vectors have previously shown to transduce cells which resulted in random 
chromosomal integration and episomal transgene expression (Duan et al. 1998; Miao et al. 
1998; Nakai et al. 1999).  
Adenoviral vectors contain a large packaging capacity and possess non-integrating properties. 
Adenoviral vectors have been used in a large number of clinical trials as either gene or vaccine 
delivery. However, there are safety concerns with the use of adenoviral vectors to deliver 
genes as it was found that the adenoviral capsid resulted in vigorous inflammatory response 
which resulted in multiple organ failure (Appaiahgari & Vrati 2015).  
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1.2 Integration of Lentiviral vectors   
Lentivirus vectors have been used to achieve long term expression and stable transduction 
within human cells (Naldini et al. 1996). Lentivirus vectors have also been used to genetically 
correct hematopoietic stem/progenitor cells from Wiskott-Aldrich syndrome and 
Metachromatic leukodystrophy patients as a form of ex vivo gene therapy (Aiuti et al. 2013; 
Biffi et al. 2013).   The use of lentivirus vectors have been further used in clinical trials for 
Parkinson’s disease (Palfi et al. 2014). Their characteristics have been shown to be 
advantageous over the use of other retroviral vectors as they possess the ability to integrate 
the gene of interest into the host chromosomes of proliferating and non-proliferating cells 
(Buchholz et al. 2009).  
Lentiviruses belong to a family of retroviruses, which are lipid enveloped viral particles that 
contain single stranded RNA sequences.  All retroviral genomes contain two long terminal 
repeats (LTR) flanking the provirus genome. The LTR alongside the transgenes incorporated 
into the viral backbone work in cis during processing of integration into the genome. The LTR 
sequences contain genes encoding the surface glycoproteins (env), structural proteins (gag) 
and nucleic-acid polymerases (pol) (Kay et al. 2001). In addition to these tandem genes, 
lentiviral vectors also contain regulatory genes; tat and rev (Maetzig et al. 2012).  
Examples of lentiviruses include, Human Immunodeficiency Virus (HIV), Feline 
Immunodeficiency Virus, Simian Immunodeficiency Virus and  Equine Infectious Anaemia 
Virus (Durand & Cimarelli 2011). The lentivirus HIV, contains two phases within its life cycle; 
infection and replication. However, the lentivirus life cycle differs from that of a typical 
retrovirus life cycle as it requires a rapid transport of the pre-integration provirus complex 
through the nuclear pores and into the nucleus (Naldini et al. 1996). The life cycle typically 
begins by the envelope proteins recognising and binding onto the host CD4 HIV-1 specific 
receptor to initiate the entry of the viron particle to the target cell (Deng et al. 1996). This 
process also involves the co-recepotors, CCR5 or CXCR4 which trigger the membrane fusion 
mechanism. Depending on the pseudotype entry either occurs by fusion or by endocytosis. 
Once in the cytoplasm the viral particle which contains the genomic RNA, undergoes an 
uncoating step and forms the reverse transcription complex (Suzuki & Craigie 2007). The 
reverse transcription complex of an HIV-1 provirus contains an accessory protein and a 
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structural gag matrix protein, together with the enzymes; reverse transcriptase and integrase 
(Bukrinskaya et al. 1998). The formation of the reverse transcription complex allows the 
synthesis of the full length viral DNA, which produces the pre-integration complex and begins 
its translocation to the nucleus. Studies have shown that different elements of the pre-
integration complex accommodates the viral entry into the nucleus. The gag matrix protein 
and the accessory protein components have been shown to facilitate nuclear transport 
(Vodicka et al. 1998). As the reverse transcriptase dissociates from the pre-integration 
complex, the nuclear translocation commences. Lentiviruses and many other retroviruses can 
diffuse through the nuclear envelope. Unlike other retroviruses, lentiviruses possess the 
ability to integrate into non-dividing cells as the pre-integration complex can pass through the 
nuclear membrane and thus highlighting its advantages as a gene therapy tool. These steps 
are further highlighted in Figure 1.  
The integration process of the proviral DNA begins with the role of integrase which is coded 
by pol. This is mediated by the binding of integrase to the U3 and the U5 sites within the LTR’s 
and this initiates a catalytic response. The first cleavage reaction occurs in the cytoplasm 
within the pre-integration complex, where the 3’terminal dinucleotide flanking the proviral 
DNA are cleaved (Miller et al. 1997). The second reaction occurs within the nucleus where 
short oligonucleotides are cleaved off either at the U3 or the U5 components of the LTR by 
the integrase, which consequently exposes the 3’OH end and thus forms a covalent bond to 
the host chromosomal DNA in the nucleosome  (Engelman et al. 1991).  
Once the integration process has taken place, translation and transcription of the provirus 
DNA depends upon the host cellular machinery. This is described in Figure 1 - Summary of the 
lentiviral  genome integrating into the host genome. The transcription process is mediated by 
Tat, where by it binds onto a regulatory element located downstream of the initiation site for 
transcription referred to as the transactivation-response element (Romano et al. 1999). The 
binding of Tat alongside cellular Cdk9 and cyclin T leads to transcription of the viral mRNA by 
an increase of ~100 fold (Likhoshvai et al. 2014; Romano et al. 1999).  
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Figure 1 - Summary of the lentiviral  genome integrating into the host genome 
The virus enters the cell through binding to the CD4 receptor. In the cytoplasm the viral particle 
begins to uncoat and exposes the genomic viral RNA (shown in red) to the cytosol. This allows the 
formation of Reverse transcription complex, where reverse transcription occurs. The resulting viral 
DNA is accompanied by Integrase and other cellular proteins to form Pre-integration complex. The 
pre-integration complex reaches the nuclear pore complex through microtubule transport and 
begins to integrate within the host genome. 
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The Rev protein then binds on to a stem loop structure, known as the Rev-response element, 
on the unspliced mRNA and mediates the translocation of this complex from the nucleus to 
the cytosol (Karn & Stoltzfus 2012). Env is transcribed as a full protein and translocated to the 
rough endoplasmic reticulum membrane and interacts with the virion (Perez et al. 1987).  The 
immature virion then undergoes a series of cleavages by virus genome encoded protease 
which begins by cleaving gag and gag-pro-pol. This consequently releases the mature 
structural proteins and enzymes; capsid, matrix protein, integrase and reverse transcription 
(Mattei et al. 2015). This therefore gives rise to a cone shaped mature HIV-1 viral particle.  
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1.3 Production of second generation Lentiviral vectors  
 
Lentiviral vectors possess the advantageous features including; (i) a large capacity for 
accommodating a transgene of choice (8-10kb) (ii) stable expression of the transgene within 
specific target cells, through the process of genomic integration. To generate a second 
generation lentiviral vector a three plasmid system is used (Figure 2). The three plasmids 
consist of the plasmid which contains the transgene of choice, the envelope plasmid and the 
packaging plasmid and this was first described by Naldini et al. in 1996. The packaging 
construct contains a human cytomegalovirus promoter (hCMV) which drives the gag, pro, pol 
expression (Naldini et al. 1996). A promoter is a small region of DNA which acts as a binding 
site for transcription factors. A CMV promoter is used as it’s known to be a constitutive 
promoter. The HIV provirus can contain specific elements such as a central polypurine tract 
(cPPT) which enhances transduction efficiency and transgene expression in non-dividing cells 
(Barry et al. 2001). Other elements include a woodchuck hepatitis virus post-transcriptional 
regulatory element (WPRE), which have shown to increase the transgene expression and viral 
titres (Zufferey et al. 1999; Klein et al. 2006). 
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Figure 2 - Schematic diagrams of the plasmids required for the generation of second generation 
lentiviral vectors 
The HIV-1 provirus, the plasmid of choice, packaging plasmid and the envelope plasmid are not 
drawn to scale. Ψ represents the packaging start site. The HIV-1 provirus contains accessory 
proteins, vif, vpr, vpu and nef. The vector contains cPPT and WPRE which have shown to increase 
the expression of the transgenes. The popular pseudotype VSV-G construct contains a CMV 
promoter and a poly adenylation tail (Poly A). The difference between this and a third generation 
lentivirus vectors is that the packaging plasmid is split into two plasmids, with one encoding Rev 
and the other encoding Gag and Pol.  
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1.4 Lentiviral pseudotypes; VSV-G and gp64 
 
Pseudotyping of viral particles is determined by the glycoproteins expressed on its viral coat. 
These glycoproteins therefore determine the cellular tropisms of the virion, specifically at the 
entry stage (Sanders 2002). HIV-1 has been known to incorporate a broad spectrum of 
heterologous glycoproteins which allow the virion to bind on to CD4 receptor as well as a wide 
range of co-receptors suitable for glycoproteins (Cronin et al. 2005). Page et al. were the first 
group to test HIV-1 pseudotyped vectors which harboured heterologous glycoproteins (Page 
et al. 1990). Three groups independently went on to show that Vesicular stomatitis virus G 
glycoprotein (VSV-G) was efficiently integrated into the HIV-1 viral particle (Akkina et al. 1996; 
Naldini et al. 1996; Reiser et al. 1996). VSV-G has become the most popular glycoproteins for 
pseudotyping lentiviruses. The advantages of using VSV-G is that the receptor for VSV is an 
ubiquitously expressed lipid membrane protein (Schlegel et al. 1983). It has also been 
reported by Finkelshtein et al. that the widely spread LDL recepter serves as a major entry 
source for the VSV-G enveloped lentivirus vectors and therefore illustrates the pan-tropism 
of this pseudotype (Finkelshtein et al. 2013). Another advantage with the use of VSV-G is that 
it produces a high titre viral vectors with the use of ultracentrifuge (Bartz et al. 1996).  
A tetracyclin-regulatable promoters have been used in order for stable cells lines efficiently 
expressing VSV-G, as VSV-G can become very toxic to cells if expressed constitutively (Ory et 
al. 1996). VSV-G has been polyethylene glycol-modified (Cronin et al. 2005), as VSV-G has 
shown to be inactivated by human serum complement (DePolo 2000), therefore making it a 
much more applicable vector for clinical use.  
A second pseudotype is the Baculovirus glycoprotein GP64. The envelope GP64 is derived 
from Autographa californica multicapsid nucleopolyhedrovirus (AcMNPV) (Kingsley et al. 
1999). Kumar and colleagues were the first to use GP64 as an envelope pseudotype for 
lentiviral vectors (Kumar et al. 2003). They showed GP64 to confer a much more restricted  
tropism and high vector titres (Kumar et al. 2003; Schauber et al. 2004). Unlike VSV-G, the 
advantage of using GP64 is not toxic to cells (Kumar et al. 2003; Cronin et al. 2005).  
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1.5 Lentivirus transgene expression within the CNS 
 
The use of lentivirus vectors to transduce cells within the CNS has been a popular approach 
by many groups. Certain groups have delivered lentivirus vectors to a neonatal rat CNS by 
intracerebroventricular injections, which results in the transduction of neuronal and microglia 
cells within the cerebral cortex (Wang et al. 2015). The restricted expression in those two cell 
types was due to the incorporation of a short hairpin RNA within the payload plasmid which 
can be used to silence the target gene expression. Other studies have shown that by delivering 
VSV-G enveloped lentivirus vectors to the lateral ventricles of a neonatal mouse brain results 
in the transduction of the ependymal cells lining the ventricles (Watson et al. 2005). Particular 
studies have also delivered lentivirus vectors to adult rodent brains by the means of 
stereotactic intracranial injections. Adult injections targeting the rat corpus striatum resulted 
in discrete GFP positive neuronal cells around the injection site (Rahim et al. 2009). Adult 
Stereotactic injections to the adult mouse external capsule resulted in transduction around 
the external capsule, cortex and a few GFP positive cells within the cerebellum, brain stem 
and the spinal cord (Lattanzi et al. 2010). Transduction was mainly situated around the 
injection site. Other studies have also shown that lentiviruses have the ability to transduce 
most of the cells within the CNS, these include neurons, astrocytes, glia cells, 
oligodendrocytes and adult neuronal stem cells (Wong et al. 2006; Mátrai et al. 2010).  
The differential targeting depends on two things; transductional and transcriptional targeting. 
The transductional targeting is modified with the use of specific envelope proteins which coat 
the viral vectors and this is referred to as pseudotyping and will be further discussed within 
the next chapter. The other is transcriptional targeting and this is achieved by using a specific 
promoter or response element which control the expression of the target gene.  
However, one of the disadvantages of using lentiviral vectors to target the CNS, is that they 
do not cross the blood brain barrier (BBB) and therefore requires topical administration of 
the vector. Another disadvantage is that to achieve large areas of transduction through the 
use of lentiviral vectors, a high copy number is required.  
A way in which the inability to cross the BBB has been overcome was by the incorporation of 
a low-density lipoprotein receptor-binding domain of the apolipoprotein B into an lentiviral 
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backbone. This allowed the lentiviral vector to cross the BBB by delivering the vector 
intravenous or intraperitoneal (Spencer & Verma 2007).  
Previous studies have demonstrated that by administering lentiviral vectors at a fetal stage of 
development results in efficient gene expression within the liver, heart, muscle and brain 
(Waddington et al. 2003; Rahim et al. 2009). As no abnormal pathology was observed within 
Rahim et al.  study this highlighted the safety of the HIV-1 lentiviral administration at a 
younger stage in development. Other advantages of administering at a younger stage of 
development include (i) the immune system at this stage is tolerant of foreign viral vectors 
(ii) immune response to the viral vector is reduced as the fetal immune system is unlikely to  
have encountered the viral infection before (iii) ratio of vector to cell is high and therefore 
increases the efficiency of gene delivery (iv) enhances vector targeting to stem cell niches  
(Karda et al. 2014).  
Another solution to overcome insertional mutagenesis is the use of Integration defective 
lentiviral vectors (IDLV) where the integrase component of the virion contains a point 
mutation (Philpott & Thrasher 2007). Therefore, this means that the lentiviral DNA cannot 
integrate into the host genome. Many different IDLV packaging plasmids have been 
generated with different point mutations within the virion integrase and have been tested in 
vitro by Apolonia et al. (Apolonia et al. 2007). The double stranded linear DNA produced by 
the non-integrating lentiviral virion exists as extrachromosomal DNA. In vitro studies have 
shown that IDLV can achieve stable transgene expression (Saenz et al. 2004) and this can be 
accomplished within primary human cell lines (Lu et al. 2004). In vivo data illustrated that 
delivery of IDLV carrying a CMV promoter driving an enhanced GFP (eGFP) via stereotactic 
injections to the adult rodent CNS resulted in GFP expression within neuronal cells within the 
mouse striatum, external capsule, lateral ventricles and the hippocampus (Philippe et al. 
2006). Many other groups have demonstrated the use of IDLV within in vivo and these include 
transduction of the mouse ocular system and the ability to partially correcting the disease 
phenotype of mice which exhibit retinal dystrophies (Yáñez-Muñoz et al. 2006). Efficient gene 
transfer was achieved with in muscle (Apolonia et al. 2007). IDLV should have a better safety 
profile in non-dividing cells as it remains episomal and therefore poses minimal risk of 
insertional mutagenesis.  
Introduction | Page 15 
1.6 AAV genome  
 
AAV is a replication defective human parvovirus which is non-pathogenic (Dong et al. 2010). 
The AAV genome is a single stranded linear DNA and has a limited packaging capacity of 4.7kb. 
Each end of the linear DNA is flanked by 145bp of inverted terminal repeats (ITR) (Srivastava 
et al. 1983). The initial 125bp pf the ITR’s consists of a palindromic sequence which forms a 
T-shaped hairpin structure, providing a 3’-hydroxyl group which consequently enhances the 
base pairing (Daya & Berns 2008). The ITR’s play an important role, as they initiate the 
synthesis of the second DNA strand. The wild type AAV genome has the ability to integrate 
into a specific locus of human chromosome 19, establishing a latent infection (Kotin et al. 
1990). The remaining open reading frame (ORF) of the AAV genome consists of a regulatory 
genes (Rep) which encodes four rep proteins; Rep40, 52, 68 and 72. The two larger Rep 
proteins, 68 and 72 are transcribed by the P5 AAV promoter and are required for DNA 
replication (Pereira et al. 1997). The P19 AAV promoter transcribes the smaller Rep proteins; 
40 and 52. The Rep40 and 52 proteins play a key role in packaging the single stranded viral 
AAV DNA into the AAV capsids (Daya & Berns 2008). The remaining ORF contains the Cap 
genes and this is transcribed by the P40 promoter. Three viral capsid proteins are translated 
and each of different size; VP1 (87KDa), VP2 (72KDa) and VP3 (62KDa) (Daya & Berns 2008) 
and are necessary for the capsid formation. They assemble in a 1:1:10 ratio to form the intact 
viral capsid (Binny & Nathwani 2012). All these components are illustrated in Figure 3.  
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Figure 3 - Illustrations of the AAV viral genome 
The Rep and Cap genes are transcribed by the three different promoters; P5, 19 and 40. The Poly A tail lies 
in between the Cap and the 3’ ITR.  The diagram is not drawn to scale. 
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1.6.1  AAV vector entry 
 
The AAV viral vector entry into a cell is complete and dependent on the helper virus which 
encodes adenovirus E1, 2, 4 and the virus associated RNA (VA-RNA) (Binny & Nathwani 2012). 
In the absence of the helper plasmid, the wild type AAV viral particle integrates into human 
chromosome 19.  
There are many serotypes of AAV which have been isolated from humans and non-human 
primates. The serotypes determine the tropisms of the AAV virion and these have been 
studied in rodents and non-human primates via systemic delivery (Karda et al. 2014).  
The life cycle begins with the binding of the AAV-2 virion typically to the cell surface receptor 
heparan sulfate proteoglycan (HSPG). Once this binding occurs the virion particle enters the 
cell through a process of endocytosis (Nonnenmacher & Weber 2012).  
Once in the cytosol the AAV virion is trafficked using microtubules to the nucleus with the 
help of the activated Rac1 protein (small signalling G-protein) and phosphatidylinositol 3-
kinase pathway (Sanlioglu et al. 2000). Particular studies have shown that conserved 
phospholipase A2 present at the N-terminus of the VP1 protein plays a crucial role in the 
infection of AAV, as mutation in this region greatly reduces the infection process (Girod et al. 
2002). The AAV particle undergoes a conformational change which exposes the VP1 and VP2 
N-terminus and releases the capsid from the endomembrane and into the cytoplasm 
(Nonnenmacher & Weber 2012). The AAV capsid then enters the nucleus through the nuclear 
pore complex. This process is still poorly understood. The capsid begins to partially uncoat 
itself and release the AAV genome. The transcriptional and translational process relies upon 
the host cellular components. The AAV viral vector cell entry is simply demonstrated in Figure 
4.  
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Figure 4 - Intracellular trafficking of the AAV-2 viral particle 
The AAV-2 viral particle binds on to the HSPG receptor which allows its entry into the cytoplasm via 
endocytosis. The virion is then trafficked to the trans-golgi network by the retrograde transport. The capsid 
undergoes a conformational change which releases it from the endosome and enters the nucleoplasm via the 
nuclear pore complex. Here the capsid undergoes a partial proteolysis and releases the AAV genome into the 
nucleoplasm. 
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1.6.2  AAV serotypes and transgene expression  
 
The maximum packaging capacity of the AAV vector was investigated by Dong et al. whereby 
they inserted various lengths of DNA ranging from 3 – 7kb into the AAV backbone (Dong et al. 
2010). Similar to other studies (Hermonat et al. 1997) the results showed that AAV vectors 
which exceeded 5.3kb could not be encapsulated and the vector yield dramatically reduced. 
They also observed that packaging vectors which exceeded the size of 5.3kb produced a low 
yield of circularized AAV viral genome copies (Dong et al. 2010).  
Pseudo-serotyping is a very powerful tool in establishing novel cellular tropisms for the AAV 
vector system. To date many AAV serotypes have been identified and some of these include; 
AAV1, 2, 3, 4, 5, 6, 7, 8, 9, rh10 and LK03 (Lisowski et al. 2014; Lisowski et al. 2015). As 
mentioned previously the target cell specificity of the AAV heavily relies on the cell surface 
receptor interaction and this consequently determines the AAV tropisms. To establish the 
tropisms of the various AAV serotypes available, many studies have administered the 
different AAV serotypes via systemic delivery to rodents and to non-human primates 
(Zincarelli et al. 2008; Gray et al. 2011; Yang et al. 2014).  
Serotype 8 has been shown to cross the BBB and transduce the CNS particularly targeting cells 
of an astrocytic morphology after adult intracranial stereotactic injections (Aschauer et al. 
2013). However, the AAV9 serotype has been shown to cross the BBB much more efficiently 
and produce a global transduction of the CNS through systemic delivery of the vector in fetal, 
neonatal and adult rodents (Fu et al. 2011; Rahim, Ams Wong, et al. 2011).  
The AAV vector system has been broadly used as a gene therapy tool due to the high neuronal 
transduction efficiency (Gray et al. 2011) and the excellent safety profile in humans (Nakai et 
al. 2005). The post mitotic status of neurons makes them a good target for non-integrating 
vectors. AAV possess the ability to maintain gene expression in non-dividing cells (Gaj et al. 
2015). However, their ability to have a global gene expression can be diminished by the 
presence of neutralizing antibodies (Gaj et al. 2015).  
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Additional advantages include lower toxicity (Daya & Berns 2008) and minimal integration 
into the host genome, therefore imposing a lower risk of insertional oncogenesis associated 
with integrating vectors such as EIAV lentivirus (Themis et al. 2005) and gamma retrovirus 
(Howe et al. 2008). However, particular studies have highlighted genotoxicity associated with 
AAV. Chandler et al. conducted a series of experiments where they observed that AAV 
integrated into the rodent RNA and accumulated within the nucleus locus which consequently 
resulted in an overexpression of retrotransposon-like 1 and microRNA 341 and thus caused 
hepatocellular carcinoma (Chandler et al. 2015).   
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1.7 Somatic-transgenic technology  
 
1.7.1 Reporter gene technology 
 
The way in which signalling pathways stimulate the transcription of specific genes, is by 
activating particular transcription factors which consequently bind on to the appropriate 
response element and thus allow transcription of the desired gene to occur. By incorporating 
a reporter gene downstream of the response element would provide a means of monitoring 
the activation of a signalling pathway (Naylor 1999).  This is referred to as the reporter gene 
technology. The first reporter gene to be used to monitor transcriptional activity in vitro was 
Chloramphenicol acetyltransferase (CAT) (Bronstein et al. 1994). CAT is a bacterial enzyme 
and the use of this was shortly followed on by β-Galactosidase, which is also another widely 
used bacterial enzyme (Naylor 1999). Another bacterial enzyme which was commonly used is 
bacterial luciferase, lux luciferase (Bronstein et al. 1994). However,  the use of a firefly 
luciferase from an American Photinus pyralis was first cloned in 1985 (de Wet et al. 1985) and 
has shown to have several folds greater sensitivity than the bacterial assays. Advantage of 
using firefly luciferase along with green fluorescent protein (GFP) is that these proteins don’t 
require any post-translational modification in order to achieve a read out and therefore their 
enzymatic activity or expression is measured according to the time of the reaction (Bronstein 
et al. 1994). Two reporter genes which have been widely used with no endogenous activity 
are firefly luciferase and GFP are the ones used during my studies. The firefly luciferase has 
been one of the most widely used reporter genes in mammalian cells due to it’s large linear 
range and it’s increased sensitivity (Joyeux et al. 1997; Welsh & Kay 1997).  
The luciferase enzyme forms a catalytic reaction with its substrate luciferin to emit light. The 
photonic emission of the luciferase expression from both in vitro and in vivo means can be 
detected by using sensitive charge-coupled device cameras (CCD). The luciferase reporter 
gene has been widely used in in vitro and in vivo applications.  
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1.7.2  In vivo applications of firefly luciferase gene transfer 
 
The use of this sensitive imaging (CCD) has previously been used with germline light producing 
transgenic (LPT). These LPT are established by luciferase reporter gene being inserted into the 
host genome, with a desirable promoter or a transcription factor binding element (TFBE) 
upstream of the biomarker. Therefore, every cell within the organism contains this foreign 
transgene construct. Thus a systemic expression can be observed each time a readout is 
taken. However, this also means that rodents will have to be sacrificed at different time points 
in order to measure the specific pathway being investigated. Zhu et al. developed a germline 
transgenic which expressed a luciferase transgene under the control of a mouse glial fibrillary 
acidic protein (GFAP) promoter (Zhu et al. 2004). In order to assess the effects of kainic acid 
within the CNS, an ex vivo bioluminescence was necessary to show that the photons 
originated specifically from the brain (Zhu et al. 2004). Similarly, Cho et al. produced 
transgenics which contained dual reporter genes; firefly and Renilla luciferase under the 
control of human GFAP and GAPDH promoter (Cho et al. 2009). They showed that GFAP driven 
expression predominated in the brain, although expression was also visible within the heart 
(Cho et al. 2009). However, one disadvantage of using germ line LPT is that localisation of 
bioluminescence to specific individual organs is very difficult as there is “background noise” 
from nearby organs. Therefore, the only way to isolate signal from individual tissues or organs 
is by sacrificing several cohorts of mice at different time points.  
Gene transfer vectors can allow the generation of somatic light producing transgenic rodents 
by achieving a degree of specific organ targeting. This was undertaken by administering gene 
transfer vectors to adult rodents. Liver bioluminescence was achieved with the use of 
hydrodynamic injections through the tail vein of mice, using a nuclear factor kappa B (NFκB) 
transcriptional response element driving a luciferase reporter gene (Osorio et al. 2013). Chen 
et al. also used hydrodynamic tail vein injections and intramyocardial delivery of plasmid 
containing a cardiac specific promoter driving a firefly luciferase, which resulted in long term 
expression within the heart but not in the liver (Chen et al. 2010). Viral vectors have also been 
used in order to achieve somatic transgenic rodents. Non-invasive bioluminescent imaging 
was achieved with the intratumoral administration of an adenovirus vector carrying a COX-2 
promoter driving luciferase (Liang et al. 2004). Adenovirus vectors have been used to target 
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the CNS of an adult mouse.  An adenovirus containing an NFκB transcriptional response 
element driving a luciferase reporter gene was administered to the adult mouse brain: long 
term expression was observed with significant up-regulation of luciferase with the addition 
of lipopolysaccharide (LPS) (Peterson et al. 2012). Lentiviral vectors have also been used to 
generate somatic light emitting rodents. Specific targeting of prostate tumours was observed 
after systemic delivery of a prostate specific lentiviral vector (Liebert et al. 2006). Targeting 
of the CNS and producing a long term light emitting organ was also achieved with the use of 
lentiviral vectors though stereotactic injection (Deroose et al. 2006). Therefore, this highlights 
that non-invasive imaging is useful for monitoring long term gene expression and thus can be 
used to study therapeutic strategies. 
However, with the use of gene transfer tools and administering them to adult rodents the 
expression of the luciferase transgene to naïve rodents resulted in a loss of expression over 
time, however this was not observed in the immune-deficient mice (Podetz-Pedersen et al. 
2014). Therefore, showing that an immune response is generated after adult administration 
of gene transfer tools.  
Previous work has shown that neonatal rodents are immune tolerant to transgene expression 
including luciferase (Ward et al. 2010). This finding was exploited by Buckley et al. where 
lentiviral vector carrying the luciferase transgene with a desirable transcription factor binding 
element, NFκB was administered, site-specifically, to neonatal rodents. To target specific cell 
types within individual organs lentivirus vectors with either VSV-G or GP64 pseudotypes were 
used. NFκB activity was demonstrated within the liver, lungs and the brain. These mice were 
also exposed to LPS to induce an immune response and this was illustrated with a significant 
upregulation of luciferase in each of these organs. Buckley et al. have established a novel 
technology whereby they can generate light-emitting somatic-transgenic animals and 
enabling the study of TF activity within an disease environment, illustrated in Figure 5 (Buckley 
et al. 2015).  
The potential advantages of using this technology are; (i) somatic-transgenesis can be 
achieved in specific organs, (ii) avoids the use of germline transgenics, which are time 
consuming, costly and a lot of animals are wasted (iii) employs the three R’s of biomedical 
animal research; reduction, refinement and replacement (iv) light can be detected from a 
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specific disease pathway in a specific organ. The use of this novel technology will be one of 
the main methods employed within my project.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5 - The generation of light-emitting somatic-transgenic animals 
Lentiviral mediated production of somatic transgenic rodents can be achieved through a single 
administration of vector on a per-animal basis. This reduces the time for production compared to germ line 
transgenic. Therefore, this addresses the three R’s of biomedical animal research; Reduction, Refinement and 
Replacement. This diagram also illustrates, when the disease pathophysiology is induced, there is an 
upregulation of the luciferase transgene. 
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1.8 Disease models 
1.8.1 Hypoxic Ischemic Encephalopathy (HIE); the Rice-Vannucci model 
 
Neonatal encephalopathy at roughly 35 weeks of gestation occurs in ~3 of every 1000 live 
births. It is a major predictor of neurodevelopmental disability and can be caused by severe 
infections during pregnancy, metabolic or genetic disorders, birth trauma, stroke and by 
various perinatal asphyxia events which is also referred to as HIE (Fernando F. Gonzalez & 
Ferriero 2008). Perinatal asphyxia occurs in 3-5 in 1000 live births, with an incidence of 
roughly 60% in low weight preterm children (Fernando F Gonzalez & Ferriero 2008; Vannucci 
& Hagberg 2004) and is a major cause of global neonatal mortality and morbidity. 25% of 
those who survive suffer from lifelong chronic disability accompanied by severe neurological 
disorders such as cerebral palsy, epilepsy, mental retardation and other disabilities. Damage 
to the CNS is mainly seen within the periventricular white matter and targeting of the 
oligodendroglia precursors, whilst in term patients lesions are present within the subcortical 
regions with particular damage to the basal ganglia (Gressens & Luton 2004). The severity of 
the disease is variable. As well as the CNS being damaged, there is also systemic organ failure, 
which kills most patients within the first week of life (Wilkinson 2010).  
There is no established treatment regime in place to date which has shown to cure to the 
cerebral oedema in severe patients. Currently hypothermia is a form of neuroprotective 
treatment which has shown to reduce the sequelae observed in these patients, however 
those with adverse HIE fail to respond to the hypothermic treatment (Wintermark 2011). 
Previously eleven randomised controlled trials of using hypothermia as a treatment for in 
term and late preterm new-borns  revealed that cooling reduces the mortality and stabilises 
the disability in the patients (Jacobs et al. 2005). However, those which suffered from severe 
HIE either died or suffered from severe disability after a 18 month follow up (Jacobs et al. 
2005).  
Hypothermia has been used in conjunction with other drug therapies  for neuroprotection 
and as a neurorestorative such as melatonin, xenon, erythropoietin and ibuprofen 
(Wintermark 2011).  
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Neonatal brain hypoxic-ischemic injury involves a reduced blood flow to the brain, followed 
by a compensation of the lost blood leading to the initiation of several signalling cascades, 
energy failures and oxidative stress. These processes are divided into three phases of injury; 
primary, secondary and tertiary (Rousset et al. 2012).  
The most extensively used rodent model of HIE was established in 1981 and is referred to as 
the Rice-Vannucci model (Rice et al. 1981). This model replicates the pathology and 
physiology of HIE and involves the ligation of the left carotid artery of the post-natal (P) rat, 
which is followed by exposure to 8% oxygen balanced with nitrogen. This model has been 
extended to the immature mouse (Sheldon et al. 1998). Surgeries are undertaken at P7 
because histological studies have shown that 7 day old rodent brains have a similar maturity 
to that of a third trimester human fetus (Taniguchi & Andreasson 2008). The occlusion of the 
left carotid artery followed by transient exposure to low percentage oxygen results in lesions 
predominantly within the ipsilateral side of the brain, with little damage present in the 
contralateral. Infarcts are primarily seen within the subcortical and periventricular white 
matter, cerebral cortex, hippocampus, striatum and thalamus (Vannucci & Hagberg 2004). 
This Rice-Vannucci model will be the disease model used within my project.  
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1.8.2 Energy metabolism within the immature brain 
 
Glucose metabolism within the immature brain confers vulnerability to hypoxic-ischemia. 
Cerebral glucose metabolism is generally low within the immature brain and is primarily 
required for the synaptic functions and the maturation of neurons (Nehlig & Pereira de 
Vasconcelos 1993). Lactate and ketone bodies can be used as an alternative to glucose for 
cerebral energy metabolism in new-born rodents and humans (Nehlig & Pereira de 
Vasconcelos 1993). In fact ketone bodies can provide up to 60% of the fuel required for the 
energy metabolism in the first two weeks from birth (Nehlig & Pereira de Vasconcelos 1993). 
The family of glucose transporters proteins (GLUT) provide glucose to individual cells and 
allows it to cross the BBB from the circulation. GLUT1 is specifically expressed within the BBB, 
whereas GLUT3 and GLUT5 are specifically expressed within neurons and the microglia 
(Vannucci et al. 1997). Other members of the GLUT family are weakly expressed within the 
CNS. Within the neonatal immature brain the expression of the GLUT family is low and thus 
the CNS at this point relies on ketone bodies and lactate as a substrate for energy (Vannucci 
et al. 1997). During hypoxic-ischemia the glucose levels drop lower than the concentration 
observed within the circulating plasma and the energy metabolism begins to heavily depend 
on the availability of ketone bodies and lactate. The levels of both these substrates drop and 
are almost undetectable during the primary energy failure and recovery phase (Vannucci 
1992).  
As the tissue energy reserves start to deplete and the cells undergo apoptosis, these events 
are highly dependent on the lack of high energy phosphates; adenosine triphosphate (ATP) 
and phosphocreatine (PCr) (Thornton & Hagberg 2015). The levels of ATP and PCr return to 
baseline and undergo another round of exhaustion due to the extent of brain injury (Thornton 
et al. 2012). During this secondary energy failure, excitatory amino acids activate the 
glutamate receptors (N-methyl-D-aspartate (NMDA) and α-amino-3-hydroxy-5-methyl-4-
isoxazolepropionic acid (AMPA)), there is an increased level of intracellular calcium, reactive 
oxygen species (ROS) due to the release of nitric oxide (Rousset et al. 2012).  
Activation of NMDA and AMPA during HI leads to an increased influx of calcium ions within 
the cytoplasm, endoplasmic reticulum, the mitochondria, the nucleus. This has been shown 
by electron micrographs analysis (Blomgren & Hagberg 2006). The mitochondrial matrix of 
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neuronal cells has been shown to accumulate higher concentrations of calcium ions and this 
results in swelling of the organelle (referred to as mitochondrial permeabilization (MP)) and 
triggers the process of apoptosis (Puka-Sundvall et al. 2000).  
The mitochondria respond to MP by releasing pro-apoptotic proteins. MP results in the 
opening of the outer and inner mitochondrial membranes which triggers the necrotic cell 
death (Bernardi et al. 2006). During MP key signalling cascades are activated which lead to 
apoptosis of the cell. It begins by the release of cytochrome c (CytC) from the mitochondrial 
cytosol, alongside other pro-apoptotic proteins; endonuclease G (endoG), apoptosis inducing 
factor (AIF) and Smac/Diablo (Thornton & Hagberg 2015). Once the pro-apoptotic proteins 
are released within the cytosol, they each undergo separate apoptotic signalling cascades. For 
instance cytochrome c  binds on to Apaf-1 which forms an apoptosome within the cytoplasm, 
this binds on to procaspase 9 and thus activates caspase 3 resulting in chromatinolysis (Figure 
6) (Thornton et al. 2012). Caspase activity is also enhanced by Smac/Diablo, however AIF does 
not interact with caspase proteins, instead it causes the activation of cyclophilin A (CypA) 
(Thornton et al. 2012). Neonatal HI studies have shown that once the AIF binds on to CypA 
forming a pro-apoptotic DNA degradation complex, this complex then translocate to the 
nucleus and thus DNA fragmentation occurs (Zhu et al. 2007). In addition to the activation of 
caspase 3 due to HI, Bax and Bcl-2 pro-apoptotic proteins are also elevated to initiate the 
process of apoptosis; this is more evident within the immature brain compared to an adult 
brain (Blomgren & Hagberg 2006).  
Bax is a member of the Bcl-2 family and during HI Bax translocates from the cytosol to the 
mitochondrial membrane, which subsequently releases further pro-apoptotic proteins. Bax 
dependent apoptosis has been highlighted within the immature brain, as previous studies 
have shown that inhibiting Bax mediated MP before the induction of neonatal HI reduced 
brain injury (Wang et al. 2010). Wang et al. were able to demonstrate the neuroprotective 
effects mediated by inhibiting Bax and further emphasise the critical role Bax plays in 
executing MP mediated cell death (Wang et al. 2010). Further neuroprotective effects were 
highlighted by Wang et al. where they overexpressed the X-linked anti-apoptotic protein 
(XIAP) within neurons in a neonatal HI brain (Wang et al. 2004). The intrinsic and extrinsic 
apoptotic pathways are illustrated further and described in Figure 6. 
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Figure 6 - Intrinsic and extrinsic apoptosis pathway after neonatal HI 
(A) During neonatal HI there is an increase in intracellular Ca2+ concentration, which causes an increase in 
reactive oxygen species (ROS). This consequently supresses the mitochondrial respiration and causes the 
release of CytC and AIF. CytC can form an apoptosome alongside with Apaf-1 and procaspase 9. This 
apoptosome then causes the activation of caspase 3 which initiates DNA fragmentation. CytC can also form 
a complex with AIF and translocate to the nucleus where DNA fragmentation leads to apoptosis. (B) In 
response to HI induced inflammation cells like astrocytes release Tumor necrosis factor – α (TNF-α) and other 
ligands (FasL and TRAIL) which activate the death receptor. This results in the binding of the adaptor protein 
TRADD to a protein kinase (RIP1). RIP1 then forms a complex with RIP3 which undergoes phosphorylation 
(necrosome) and causes an influx of ROS and results in necroptosis. Alternatively, the TRADD/RIP1 complex 
can cause the activation of caspase 8, which cleaves BH-3 interacting domain (BID) to form tBID, which leads 
to apoptosis (Thornton & Hagberg 2015). 
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During cerebral HI in neonates it has been shown that the BBB becomes vulnerable and results 
in disturbance within the BBB protein expression, however there were signs of recovery and 
compensating loss by an increased expression of right junctions within the BBB (Ek et al. 
2015).  
In response to HI a rapid activation of number of cells occurs. The first set of cells to react in 
defence to the inflammation are microglia, mast cells and astrocytes (McRae et al. 1995; Jin 
et al. 2009; Burda & Sofroniew 2014). This is then followed by the activation of natural killer 
cells, neutrophils during the reperfusion.  
The role of astrocytes during HI will be the main cell type being investigated within my project.  
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1.8.3 Type II Gaucher mouse model 
 
There are three types of Gaucher disease which exhibit different phenotypes. Type I is a non-
neuropathic Gaucher disease and the most common of the three. The phenotype involves 
growth retardation, anaemia, splenomegaly and skeletal pathologies (Masi & Brandi 2015). 
Type III is associated with neurological symptoms which present during childhood and in adult 
hood.  
Infantile Type II Gaucher disease is an autosomal genetic disease which is common amongst 
the Ashkenazi Jews. This genetic disease results in an inherited deficiency of the lysosomal 
enzyme β - glucocerebrosidase, which results in degenerative neurological disorder (Pastores 
et al. 1993). Glucocerebroside is widely distributed within the cell membrane and broken 
down by the lysosomal enzyme β - glucocerebrosidase. The inability of the degradation 
process to take place due to this rare disease results in the accumulation of glucocerebroside, 
predominately seen within the liver, spleen and the bone marrow (Orvisky et al. 2000). The 
CNS of these patients exhibit astrogliosis, reactive microglia and neuronal loss (Wong et al. 
2004). A mouse model replicating the severe neurological deficits exhibited by these patients 
was created by Enquist et al. (Enquist et al. 2007). Within this mouse model they have knocked 
out the β – glucocerebrosidase gene and therefore created a severe phenotype where the 
knock outs die at day 12 of development.  
As a hallmark of this disease is astrogliosis, this makes this disease model an ideal candidate 
to investigate the increase proliferative astrocytic cells with the use of somatic transgenic 
technology.  
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1.9 Role of astrocytes within the CNS 
 
As one of the aims of my project is to target astrocytes with lentiviral vectors and monitor the 
expression levels of specific proteins after hypoxic-ischaemic insult, here I have described in 
greater detail the role of astrocytes within the CNS.  
Astrocytes are star shaped glia cells and are the most abundant cell type within the CNS. There 
are two types of astrocytic cells and they are divided based upon their location within the 
CNS, biochemistry and their morphology. Protoplasmic astrocytes are largely found within 
the cortex and hypothalamus, whereas the fibrotic astrocytes are found sparsely throughout 
the CNS, in particular within the white matter regions (Alvarez et al. 2013). Due to the broad 
spectrum of roles that astrocytes undertake and their ability to adapt to their environment 
and change the expression of certain proteins, it has become increasingly difficult to 
differentiate subpopulations of astrocytes (Kimelberg 2004).  
Astrocytes play an important role within the functionality of the brain by maintaining the 
glucose and lactate metabolism, clearing of potassium ion from the extracellular space, 
maintaining an ionic balance for nearby surrounding neurons, regulating the two most 
copious neurotransmitters glutamate and GABA and most importantly producing an immune 
response (Orellana & Stehberg 2014). Astrocytes express many membrane receptors which 
regulate key neurotransmitters and key ion channels which respond to the release of 
neurotransmitters within the synaptic cleft. The release of these transmitters responds to the 
concentration of intracellular calcium ion concentration (McCarthy & Salm 1991).  
The BBB maintains the homeostasis environment for the CNS. The BBB comprises mainly 
highly specialised endothelial cells and these work in close proximity with cells such as 
astrocytes, neurons, pericytes and microglia (Alvarez et al. 2013). Astrocytes play an 
important role in determining the phenotype of the BBB. They way in which they do this is by 
forming a close interaction with the CNS vasculature with their endfeet, this is referred to as 
neurovascular coupling (Alvarez et al. 2013). Studies have shown that through the astrocyte-
neuron interactions, upon glutamate mediated signalling, nitric oxide is released from the 
neurons alongside derivatives of arachidonic acids released from neurons, to control cerebral 
blood flow (Attwell et al. 2010).  
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In response to cerebral damage, astrocytes undergo a morphological change from their 
resting state to their reactive state. The morphological changes which astrocytes undergo is 
hypotrophy, which is instigated by the over expression of an intermediate filament; GFAP. 
The process of reactive astrocytes is referred to as astrogliosis. The over expression of GFAP 
has been used as a hallmark for astrogliosis, however the function of GFAP during astrogliosis 
is largely unknown (Kamphuis et al. 2012). Protoplasmic astrocytes predominantly express 
GFAP (Kimelberg 2004).  
The transcription factor NFκB has been shown to instigate the transcription of genes in 
response to inflammation, cellular stress and cellular death. The up-regulation of this 
transcription factor has also been implicated within the brain in response to damage and 
neurodegeneration (Schmidt-Ullrich et al. 1996). The expression of NFκB has been shown to 
occur during astrogliosis (Acarin et al. 2000).  
The JAK-STAT signalling pathway plays a major role in the genesis of astrocytes. There are 
many signal transducer and activator of transcription (STAT) proteins, but specifically STAT3 
has been shown to mediate differentiation of astrocytes (Hong & Song 2014). As well as being 
involved in astrocyte differentiation, STAT3 has also been implicated in astrogliosis (Acarin et 
al. 2000).  
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1.10 Hypotheses and aims 
1.10.1 Hypotheses 
• Using vectors delivering luciferase under the transcriptional control of regulatory 
elements or promoters, it is possible to achieve astrocyte and neuron selectivity and 
prolonged somatic transgenesis within the CNS. 
• Delivering suitable biosensor (NFκB, SFFV. GFAP and STAT3) vector carrying luciferase 
as a reporter gene, is it possible to identify the temporal and spatial activation of these 
key factors in an evolving HIE lesion and so predict the progression and severity of the 
HIE lesion.  
 
1.10.2 Aims 
• Establish the use of somatic transgenic bioimaging within the CNS of a neonatal 
mouse. 
• Identify the best pseudotyped lentivirus vector and timing of the administration to 
target delivery to appropriate cell type i.e. astrocytes or neurons. 
• To set up the HIE mouse model using outbred CD1 mice and to validate the model. 
• To monitor the extent of astrogliosis and inflammation in the HIE mouse model using 
somatic transgenic technology. 
 
Individual hypothesis and aims for each results chapter are mentioned within each section.  
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2 Materials and Methods 
 
The list of reagents and the recipe for buffers are detailed in appendix section 11.1 “Reagents 
and buffers” on page 149. All the methods mentioned within this chapter were performed by 
myself.  
2.1 Bacterial transformations and maintenance of E.coli  
 
2.1.1  Transformation of ccdB or One Shot Stbl3TM bacterial cells 
 
ccdB or One Shot Stbl3TM  chemically competent E.coli cells were first thawed on ice for each 
transformation. 10pg to 100ng of DNA was added to each 50µl vial, gently mixed and 
incubated on ice for 30 minutes. The cells were heat shocked for 45 seconds at 42°C. The cells 
were placed on ice for 2 minutes, after which 250µl of SOC media (containing 2% Vegetable 
Peptone, 0.5% Yeast Extract, 10mM NaCl, 2.5mM KCl, 10mM MgCl2, 10mM MgSO4, and 
20mM Glucose) was added and the cells were shaken at 225rpm, 37°C for 1 hour. The cells 
were spread on an LB agar plates containing ampicillin (100µg/mL). The plates were incubated 
over night at 37°C, after which colonies were selected by using a sterile 10µl pipette tip and 
grown overnight in LB at 225rpm and 37°C. Plasmid DNA was prepared using Qiagen Mini-
prep kits and following the manufacturers guide lines. Larger volumes of plasmid DNA were 
prepared using Qiagen Maxi-prep kits, once again, following the manufacturer’s instructions.  
 
2.1.2  Growth medium 
 
E.coli transformed with plasmid were grown in LB media at 37°C supplemented with ampicillin 
(100µg/mL) and agitated at 225rpm. For long term storage, bacterial cultures were stored at 
-80°C in a 1:3 ratio of glycerol.  
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2.2 Gateway cloning  
 
To generate lentiviral reporter vectors used in this project a Gateway cloning (Life 
Technologies, Galsgow, UK) system was used.  The lentiviral plasmid and the AAV plasmid 
contained a Gateway construct, which could be removed and replaced by any promoter or 
response element of choice by a simple recombination (permitting that the promoter or 
response element did not exceed the length of 1.6kb). The lentiviral and AAV plasmids which 
were used in this study contained the following features; a minimal promoter upstream of 
the Gateway cassette, followed by a 3xFLAG, FLuc and 2A-eGFP (pLNT-GW-Fluc-2A-GFP). 
These features are illustrated in the lentiviral plasmid in Figure 7.   
  
Figure 7 - Plasmid construct adapted from Buckley et al. 2015 
The illustration shows a second generation lentivirus plasmid with the following features packaged 
between two 3’ long terminal repeats (LTR); central polypurine tract (cPPT), Gateway, 3xFLAG tag, 
luciferase reporter gene (Fluc), 2A bicistronic linker, enhanced green fluorescent protein (eGFP) and 
a woodchuck hepatitis virus post-transcriptional regulatory element (WPRE). 
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2.2.1 Polymerase chain reaction (PCR) 
 
PCR was used to amplify the GFAP truncated promoter. PCR reactions were performed in a 
standard reaction mix in a total volume of 50µl, using Phusion High-Fidelity DNA Polymerase. 
The reaction mixture contained 100ng plasmid, 10µl 5X Phusion HF buffer (containing 7.5 mM 
MgCl2), 1µl of DMSO, 0.5µM of each primer, 200µM of each dNTP, 1U Phusion High-Fidelity 
DNA Polymerase. PCR cycling conditions used included an initial denaturation step of 97ᵒC for 
5 minutes, followed by 35 cycles of 98ᵒC for 30 seconds, annealing primers at 50ᵒC for 30 
seconds and extensions at 72ᵒC for 30 seconds.  
 
2.2.2 Restriction enzyme digest 
 
1µg of DNA was digested in a final volume of 30µl containing the following; 1x buffer (supplied 
by the manufacturer), 1x BSA (0.1mg/mL) and the restriction enzyme (volume would not 
exceed 10% of total reaction volume). The digests were carried out for 2 hours, after which 
were verified by agarose gel electrophoresis.   
 
2.2.3 Removal of fragments from gel electrophoresis  
 
Agarose gel electrophoresis was used to resolve DNA fragments followed by cloning PCR or 
restriction enzyme digests. Varying percentages of agarose gel (1-3%) were made using 
agarose dissolved in 1x TAE, followed by the addition of SafeView for the visualisation of the 
DNA. The DNA samples were loaded onto the gel using a DNA loading buffer and a 1kb plus 
ladder was also loaded to show the size of the DNA bands. The gels were electrophoresed at 
a voltage between 70-100V, after which the DNA fragments were visualised under ultra-violet 
light (UV). The DNA fragments were extracted using a clean scalpel blade under UV, after 
which a QIAquick gel extraction kit was used following the manufacturer’s instructions.  
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2.2.4 DNA ligation 
 
The digested GFAP promoter and the digested pENTR1A plasmid were ligated using this 
method. Digested DNA vector fragments were ligated using a vector to insert ratio of 1:3 
(molar) and carried out in a final volume of 20µl; 2x ligase buffer and 1 unit of quick ligase. 
The ligation mix was incubated at room temperature (RT) for 5 minutes, after which they were 
transformed into ccdB or One Shot Stbl3TM  E.coli cells.  
 
2.2.5 Gateway recombination  
 
25ng of the pENTR1A vector containing the promoter or transcription factor binding element 
was added to 75ng of the pLNT-GW-JDG, this reaction mixture was made up to 5µl with Buffer 
TE pH 8 and 1μl of Clonase was added. The reagents were incubated at 25°C for 1 hour, after 
which 0.5μl Proteinase K was added and left for 10 minutes at 37°C. 3μl of this recombination 
reaction was added to competent ccdB E.coli cells and transformation using LB agar plates 
containing ampicillin (100µg/mL) was followed. 
 
2.2.6 Cloning of the GFAP biosensor  
 
The GFAP truncated promoter was PCR amplified (Section 2.2.1 “Polymerase chain reaction 
(PCR)” on page 38) from the plasmid pTYC-GfaABC1D-eGFP, using primers which were either 
flanked with BamHI or XbaI (Forward primer (BamHI) – 
TATCGCTTGGATCCTAACATATCCTGGTGTG and Reverse primer (XbaI) – 
TACTAATCTAGACTAGGAGCAGCGGAGGTG). The PCR produce was ran on a 1% agarose gel 
and the band corresponding to 700 base pairs was gel extracted (Section 2.2.3 “Removal of 
fragments from gel electrophoresis” above), followed by a restriction digest with BamHI and 
XbaI  (Section 2.2.2 “Restriction enzyme digest” above). The pENTR1A was digested by BamHI 
and XbaI and the GFAP promoter and the digested pENTR1A plasmid were ligated (Section 
2.2.4 “DNA ligation” above). After which the ligation product was digested again with BamHI 
and XbaI to confirm whether the GFAP promoter had been cloned in. Once confirmed a 
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gateway recombination reaction was set up (Section 2.2.5 “Gateway recombination” above). 
Once I had the successfully gateway recombined the GFAP into the lentivirus gateway 
plasmid, I digested the plasmid with BamHI. The results are shown in Figure 8.  
 
 
 
 
 
 
 
 
Figure 8 - Restriction digest on pLNT-GFAP-luc-2A-GFP plasmid 
The pLNT-GFAP-luc-2A-GFP plasmid was digested with BamHI and the GFAP promoter was 
digested out at 700bp. The remaining backbone is shown at the top of the figure which runs 
at ~11kb.  
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2.3 Cell culture 
 
2.3.1 Growing up HEK293T cells 
 
HEK293T cells were supplemented with DMEM with 10% FCS and grown in either T75cm2 or 
T175cm2 tissue culture flasks and incubated at 37°C and 5% CO2. The cells were passaged 
when they had reached a confluency of 80-90%. The cells were washed with Dulbecco’s 
phosphate buffered saline (1x PBS) and incubated with 0.05% trypsin in EDTA for 2 minutes. 
The cells collected were centrifuged for 5 minutes at 1500rpm at 4°C. After which the cell 
pellet collected was re-suspended in fresh DMEM and transferred to a new tissue culture 
flask.  
 
2.3.2 Long term storage of cells 
 
Once the cells were 90% confluent in a T175cm2 tissue culture flask, the cells were centrifuged 
and the cell pellet was re-suspended in freezing medium; 90% FCS and 10% DMSO. 1mL of 
this re-suspension was transferred to a cryovial. The cells were frozen slowly in an isopropanol 
freezing box in the -80°C freezer. They were transferred out of the freezing box the following 
day and stored at -80°C.  
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2.4 Lentivirus production  
 
A three plasmids system was used when producing lentivirus, to produce a second generation 
lentivirus (Demaison et al., 2002). Envelope plasmids VSV-G (pMD.G2; Vesicular Somatitis 
Virus glycoprotein) and gp64 (pgp64; Baculovirus - glycoprotein 64) determine cellular 
tropism of the lentivirus (Barrette et al., 2000). The packaging plasmid pCMVΔR8.74 
containing the gag and pol genes provides factors which allow the lentivirus vector to 
integrate into the host genome (Figure 9). The envelope and the packaging plasmids were 
produced at a large scale by Aldevron (North Dakota, USA).  
 
Figure 9 - Three plasmid lentivirus vector production 
The diagram shows the three plasmid lentivirus system which we use to produce viral lentivirus 
particles. A virus plasmid which contains your transgene of choice is used, alongside a packaging and 
an envelope plasmid.  
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2.4.1 Production of VSV-G and gp64 pseudotyped lentiviral vectors  
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2.4.2 Titration of lentiviral vectors using p24 Antigen ELISA 
 
Lentiviral vectors were diluted; 1µl in 999µl dH20, 10µl of the dilution added to 990µl dH20 
and finally 100µl of the last dilution to 900µl dH20. The dilutions of lentiviral vectors was 
added to the antibody coated wells. Standards were also prepared following the 
manufacturer’s instructions. The absorbance of each well was then read at 450nm and the 
quantity of p24 reagents were calculated using the standards. 
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2.5 Adeno-associated virus (AAV) vector production 
 
A three plasmid transfection protocol was carried out for the production of AAV2/8 vector. 
This included the use of a packaging plasmid, which carries the rep and cap genes, a helper 
plasmid (pHGT1) carrying the adenoviral helper genes and a plasmid of choice containing the 
desirable transgene (Binny and Nathwani, 2010). The packaging plasmids were provided by 
University of Pennsylvania and the helper plasmid by Harvard University.  
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2.5.1 Three plasmid AAV transfection 
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2.5.2 Virus purification using HPLC  
 
AAV particles were purified by affinity chromatography using an ÄKTA HPLC system (GE 
Healthcare UK Ltd, Buckinghamshire, UK). For the specific purification of AAV2/8 a 1mL 
Sepharose (GE Healthcare UK Ltd, Buckinghamshire, UK) packaged column (Generon, 
Maidenhead, UK) was used.  
All the lines were washed with filtered 20% ethanol and the followed by filtered PBS (pH 7.5) 
through line A and 50mM of filtered Glycine (pH 2.7) through line B. After which the 
Sepharose column was attached and equilibrated with filtered PBS at a flow rate of 1mL/min 
until the absorbance readings were stable. The AAV supernatant and the cell lysates collected 
were passed through the column at a flow rate of 1mL/min, through line A. The waste was 
collected from the first run as it can be passed through the column again to ensure that all 
the viral particles are bound to the column. PBS was passed through the column to remove 
all the unbound protein and DNA. Line B was placed into 50mM of Glycine (pH 2.7) to elute 
the viral particles from the column. The eluates were collected in 1mL FACS tubes with 30µl 
of 1M Tris (pH 8.8) to neutralise the glycine. The fractions which contained vector were 
identified by the peaks in absorbance at 260 and 280nm. The fractions were collated and 
syringed into a 10KDa cut-off dialysis cassette (Slide-A-Lyzer Thermo Scientific, 
Loughborough, UK) and left spinning overnight in PBS to remove the glycine and restore the 
pH.   
 
2.5.3 Concentrating AAV vector  
 
To concentrate the AAV2/8 viral particles; an Amicon ultra 15 Centrifugal filter 100000 (Merck 
Millipore, Hertfordshire, UK) was primed with 5mLs PBS. This was centrifuged for 5 minutes 
at 4000rpm at 4°C. The waste was discarded and the vector collected was added to the filter 
and again centrifuged for 5 minutes at 4000rpm at 4°C. The vector remaining in the Amicon 
ultra membrane was removed and placed in to a clean 1.5mL eppendorf. The membrane was 
washed with 200µl of 1x PBS to collect further vector remaining on the filter. The total virus 
collected was sterilised by using a 1.5mL eppendorf with a 0.22µm filter (Costar, London, UK). 
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The vector was centrifuged at 13,000rpm for 3 minutes. The vector was stored either at 4°C 
for short term storage or -80°C for long term storage.   
 
2.5.4 Coomassie gel to reveal capsid proteins 
 
In order to assess the integrity of the viral proteins I ran a denaturing agarose gel. The viral 
integrity was visualised by using a Coomassie stain, which would show the three structural 
capsid proteins; VP1, VP2 and VP3 at the correct sizes, shown in Figure 10.  
 
20µl of 2x Laemmli buffer (Sigma) was added and re-suspended with 20µl of concentrated 
vector. The mixture was heat shocked for 5 minutes at 95°C and briefly centrifuged; 9000rpm 
for 1 minute. 30µl of the denaturing protein was loaded onto a pre-cast 10% acrylamide gel, 
alongside a pre-stained protein ladder broad range (New England Biolabs). The gel tank was 
filled to the top with MOPS buffer before running at 125V for an hour. Once the loading buffer 
had run to the bottom of the gel, the gel was transferred to a plastic tray, where it was 
Figure 10 - Coomassie gel for an AAV vector 
The coomassie gel shows the VP1, VP2 and the VP3 proteins from the AAV capsid proteins.  
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covered in approximately 1cm of Coomassie blue staining buffer. The plastic tray was covered 
in aluminium foil and placed on a rocker for 2 hours at RT. After which the Coomassie dye was 
removed and a destain solution was added to the plastic tray and left to incubate for a further 
2 hours. The gel was visualised using white light (Bench top UV trans-illuminator, Uvp Biodoc 
it Imaging system, Cambridge, UK) to see if the three structural proteins were present.  
 
2.5.5 Alkaline gel to quantify vector DNA 
 
To quantify the viral DNA, samples were run on a denaturing alkaline gel. The alkaline gel was 
made by adding 0.8g of agarose to 98mL ddH2O and heated to dissolve. Once the temperature 
of the gel mixture dropped below 50°C, 2mL of 50x alkaline electrophoresis buffer was added 
and the gel was left to set in a gel tray.  8.5µl of alkaline sample loading buffer was added to 
25µl of vector. The vector was diluted down by 5 fold and then added to 8.5µl of alkaline 
sample loading buffer and the total volume made up to 25µl by adding ddH2O. Viral samples 
were placed on ice. The samples alongside 5µl of Hyperladder I were ran at 20V at 4°C 
overnight. The next day the gel was gently agitated in 300mL of 0.1M Tris (pH 8.0) for 1 hour. 
The gel was transferred to 100mL of 4x Gelred solution and left for a further 2 hours agitating 
in the dark. After which the gel was rinsed twice with tap water and then visualised using the 
UV trans-illuminator. The alkaline gel for the AAV8-NFκB-luc-2A-GFP vector is shown in Figure 
11. The gel image was analysed in Image J for quantifying the viral DNA, where by the band 
intensity is compared against the standard (DNA ladder).  
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Figure 11 - Alkaline gel for AAV-NFκB-luc-2A-GFP 
The AAV vector dilutions were ran on to a alkaline gel. The 3.3kb band represents the size 
of the vector from 5’ITR to 3’ITR. An Hyperladder I was also loaded on this gel.  
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2.6 In vitro experiments 
2.6.1 Neuronal and glia cell separation  
 
The day before neuronal and glia separation, 24 well plates were coated. A 1:200 dilution of 
1mg/mL of Poly-D-lysin hyrdobromide (PDL) in PBS was added to each well and left for 2 hours 
at 37°C. Wells were washed twice with PBS and coated with a 1:400 dilution of 1mg/mL 
Laminin in PBS and left over night at 37°C. The following day, neonatal brains from 3 day old 
mice were harvested and placed in a 3mLs of Hanks Balanced Salt Solution (HBSS) without 
calcium and magnesium. The skull was removed and the brains were immediately placed in 
2mLs of ice cold PBS. They were weighed and then cut into small pieces before adding again 
to PBS. Following the Neuronal Isolation MACS kit protocol provided by the manufactures, 
two fractions were eluted; one was a neuronal faction the other was a glia faction. The laminin 
was aspirated from each well and 1 x 106 cells were seeded in each plate. Neurobasal media 
supplemented with 10mLs of 50x B27, 5mLs of 100x Stretomycin and 0.75mLs of 200mM 
Glutamine was added to the cells. The primary cells cultures were left for 48 hours before half 
the media was replaced with fresh neurobasal media.  
 
2.6.2 Lentiviral transduction of neuronal and glia primary cell lines 
 
Primary neuronal and glia cells were transduced with either VSV-G or GP64 pseudotyped 
lentivirus reporters at an MOI of 10. 48 hours after transduction small molecule agonists were 
added, as previously described Buckley et al. (Buckley et al. 2015). The cells were kept in 
neurobasal media. An example of primary neuronal cells transduced with lentivirus vector are 
shown in Figure 55 on page 155. Cell lysates were collected at 72 hours post transduction by 
adding 500µl of 1x Lysis buffer. To 20µl of the cell lysates 1.5mM of luciferase was added and 
the luminescence was measured using FluoStar Omega microplate reader. The results were 
analysed in MARS data analysis data software (BMG labtech). The relative light units were 
normalised to the total protein concentration by conducting a protein assay.  
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2.7 Protein assay 
 
The protein assay was conducted by using the Pierce BCA Protein Assay Kit (Thermo-Scientific, 
Glasgow, UK). Samples were loaded alongside BSA standards, described in the manufactures 
protocol provided. The samples were loaded into a 96 well plate. After which 200µl of WR 
reagent (1 part BCA reagent B and 50 part BCA reagent A) was added to each sample, including 
the standards. The samples were incubated at 37°C for 30 minutes, before being placed in a 
FluoStar Omega microplate reader where the sample readings were taken at 490nm. The 
results were analysed in MARS data analysis data software. 
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2.8 In vivo experiments   
 
The outbred CD1 mice used in this study were supplied by Charles Rivers. All animal 
experiments conducted were in agreement with the Home Office guidelines and institutional 
guidelines at University College London and under project licences held by Dr. Simon N 
Waddington (PPL 70/6906 and PPL 70/8030).  
 
2.8.1 Neonatal intracranial injections of viral vectors  
 
On the day of birth, mice were subjected to brief hypothermic anaesthesia and followed by 
intracranial injections of concentrated lentiviral vector (~1x109 viral particles/mL) or AAV 
(~1x1013 viral particles/mL) (5µl in total) into the cerebral lateral ventricles using a 33 gauge 
Hamilton needle (Fisher Scientific), following co-ordinates provided by Kim et al. 2012. The 
mice were then allowed to return to normal temperature before placing them back in the 
dam.  
 
2.8.2 Neonatal intravenous injections of viral vectors  
  
On the day of birth, mice were subjected to brief hypothermic anaesthesia followed by 
intravenous injections of viral vectors into the superficial temporal vein, with a total volume 
of 20µl. This was done by using a 33 gauge Hamilton needle. They were then allowed to return 
to normal temperature before placing them back in the dam.  
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2.8.3 Bioluminescence imaging after intracranial or intravenous injections  
 
Mice were either anesthetised with Isoflurane or remained unanaesthetised, and received an 
intraperitoneal injection of 10-300µl (volume dependent on the stage of development of 
mice) of 15mg/mL of D-luciferin. Mice were left for 5 minutes before they were imaged using 
the IVIS machine between 1 second and 5 minutes. The regions of interest (ROI) were 
measured using Living Image Software (Perkin Elmer, Coventry, UK) and expressed as photons 
per second per centimetre squared per steradian (photons/second-cm2/sr).  
 
2.8.4 Assessing LPS induced inflammation 
 
A subset of mice (mice which received an intracranial injection of lentivirus vector carrying 
the luciferase transgene) received an intraperitoneal injection of Lipopolysaccharide-EB 
ultrapure (25mg/mL; LPS, Source Bioscience, Nottingham, U.K). Whole body bioluminescence 
imaging was then conducted.   
 
2.8.5 Rice-Vanucci HIE model  
 
This surgical procedure was carried by myself. At day 7 of development pups were 
anaesthetised using Isoflurane and their left carotid artery was ligated using an 8.0 suture 
(Rice et al., 1981). The open wound was closed using tissue adhesive and the pups were 
allowed to recover using a recovery chamber. The mice were returned to the dam for 1 hour, 
after which they were exposed to 10% oxygen in nitrogen for 90 minutes. After this, the mice 
were exposed to atmospheric air for 10 minutes and allowed to recover before being returned 
to the dam. Brain samples were collected at certain time points after surgery. Procedures 
were carried out following the UK Home Office approved guidelines. 
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2.8.6 Bile duct ligations 
 
The bile duct ligations were carried out by Dr. Simon N Waddington. Mice at the age of 6 
weeks were anaesthetised using Isoflurane. A small incision was made on their abdomen and 
the peritoneal cavity was opened. The liver and the bile duct was exposed. The common 
hepatic duct downstream of the medium and left liver lobes were ligated with a suture. The 
liver was carefully placed back into the abdominal cavity and abdomen was closed with 
subcuticular sutures. The mice were administered subcutaneously with morphine (2.5mg/kg 
– supplied by the Veterinarian at BSU).  The mice were left to recover in a heat chamber set 
at 37°C, before being placed back in their dams.  
 
2.8.7 Collecting organs - perfusions of mice 
 
Mice were anaesthetised using Isoflurane. Their right atrium was incised and 10mLs of 1x PBS 
was injected into the left ventricle. The brain tissue was stored in 4% PFA for 24 hours. The 
skull was removed and the brain tissue was fixed in 4% PFA for another 24 hours. The tissues 
were stored in 30% sucrose at 4°C, until sectioned. 
 
2.9 Ex vivo Luminometry 
 
Tissue samples were lysed by adding 500µl of 1x Lysis buffer (Promega) and homogenised. 
The homogenates collected were centrifuged for 10 minutes at 13,400 rpm and the protein 
released from the lyses step was collected. Each sample was loaded on to a white 96 well 
plate. 1.5mM of luciferase (Promega) was added at a 1:1 ratio to the sample. FluoStar Omega 
microplate reader (BMG labtech) was used to process the samples. The results were analysed 
in MARS data analysis data software (BMG labtech). 
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2.10 Processing tissue and immunohistochemistry 
 
2.10.1 Transverse sectioning of brains 
 
The brain samples collected were mounted on to a sledge microtome (Thermo-fisher, 
Glasgow, UK) platform using an embedding matrix OCT. This was temperature controlled by 
dry ice. Transverse (coronal) sections were cut at 40µm and the sections were then stored in 
TBSAF at 4°C.  
 
2.10.2 Free-floating peroxidase immunohistochemistry  
 
Representative sections of the mouse brain were selected and placed in a 6 or 24 well plate 
containing 1x TBS. Sections were treated with 30% H2O2 for 30 minutes. They were blocked 
with 15% of a specific serum (specificity dependent on the primary antibody) in TBST for 30 
minutes. This was followed by the addition of primary antibody in 10% serum and TBST and 
left on a gentle shaker over night at 4°C. The following day the sections were treated with the 
secondary antibody (1:1000 dilution) in 10% serum in TBST for 2 hours. The sections were 
incubated for a further 2 hours with Vectastain ABC. 0.05% of 3,3’-diaminobenzidine (DAB) 
was added and left for a couple of minutes. Sections were transferred to ice cold 1x TBS.  Each 
individual brain section was mounted on to slides and left to dry for 24 hours, the sections 
were placed from the olfactory bulbs to the cerebellum by using a mouse brain atlas website 
(http://mouse.brain-map.org/static/atlas). The slides were dehydrated in 100% ethanol and 
placed in Histoclear for 5 minutes before being coverslipped.  
 
2.10.3 Free-floating fluorescence immunohistochemistry  
 
A similar protocol was followed as with the immunoperoxidase stain; however, the sections 
were not treated with 30% H2O2 on day one of staining. The following day the sections were 
incubated with biotinylated secondary antibodies for 2 hours. Sections were incubated with 
a fluorescent secondary antibody for 2 hours. The sections were covered in aluminium foil 
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and treated with DAPI (5mg/mL) for a couple of minutes. They were transferred to ice cold 1x 
TBS.  Each individual brain section was mounted on to slides and left to dry for a couple of 
hours. Once dried the slides were coverslipped using Fluromount G (Ebioscience, Hatfield, 
UK).  
 
2.11 Statistical analysis 
 
Statistical analysis for in vivo data was performed using Student’s one-tailed t-test. For 
experiments comparing two groups, area under the curve was analysed again by using 
Student’s one-tailed t-test or by a repeated measures two-way ANOVA, Bonferoni post-hoc 
multiple comparison test (Software – Graphpad Prism 6).  
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3 Results I – Neonatal intracranial injections  
3.1 Intracranial injections to a neonatal mouse brain 
 
Previous work conducted by Kim et al. has demonstrated coordinates to use in order to target 
the lateral ventricles of a P0 neonatal C57BL/6J mouse (Kim et al. 2013). To confirm whether 
these measurements targeted the lateral ventricles within a new-born CD1 mouse, I used 
different coordinates to target the CD1 neonatal mouse brain by using tattoo ink. I 
hypothesised that coordinates demonstrated by Kim et al. would target the lateral 
ventricles of a new-born outbred CD1 mouse.  
 
Figure 12 - Illustration of intracranial injection coordinates 
In order to determine what areas of the mouse CNS was being targeted by intracranial 
injections, I chose three different coordinates for the intracranial injections, as shown in the key. 
The coordinates were formed by measuring 1mm from the sagittal suture and either 1, 1.5 and 
2mm from the bregma, as shown in Kim et al. (Kim et al. 2013).  
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After using these three different coordinates, along with going 1mm deep (Figure 12) to inject 
the pup heads with a 33 gauge Hamilton needle and tattoo ink the heads were cut coronally 
across the coordinates. During this process the pups were subjected to brief hypothermic 
anaesthesia. Figure 13 further illustrates the location of the brain being targeted by the 
intracranial injections. Using 1mm by 1mm targeted the external capsule. Whereas 1mm by 
1.5mm hit the external capsule and the lateral ventricles, and the ventricles were further 
targeted by the 1mm and 2mm coordinates. These findings follow those shown by Kim et al. 
(Kim et al. 2013). This therefore highlighted that the 1mm by 2mm coordinates enable a wider 
spread of vector as it shows targeting of the lateral and third ventricles.  
Figure 13 - Coronal view of the pup brain showing targeting of the CNS with varying coordinates 
for intracranial injections. 
The external capsule (EC) was targeted by injecting 1mm from the sagittal suture and 1 or 1.5mm 
from the bregma. The lateral ventricles (LV) were targeted by the 1.5 and 2mm distance from the 
bregma. The third ventricle (3V) was targeted by 2mm from the bregma.  
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3.2 Validating neonatal intracranial injections of lentivirus vector 
 
As previous work conducted by Rahim et al. has shown that intracranial fetal injections 
resulted in a wide spread transgene expression (Rahim et al. 2009).  I hypothesised that 
intracranial injections of lentivirus vector to the neonatal CNS would result in a widespread 
expression of the relevant transgene.  
In order to test this hypothesis, I began by validating two lentivirus vectors within the 
neonatal CNS. The two lentivirus vectors were a second generation VSV-G pseudotyped pCCL-
SFFV-GFP and LTR1-SFFV-GFP.  The LTR1 lentivirus vector has most of the HIV remnants 
removed compared to a standard pCCL lentivirus vector and thus marking it arguably safer to 
use.  
The titre of the two lentivirus vectors differed as the generation VSV-G pseudotyped pCCL-
SFFV-GFP vector had a titre of of ~1×109 viral particles/mL and the VSV-G pseudotyped LTR1-
SFFV-GFP vector had a titre of a log lower, ~1×108 viral particles/mL. Both lentivirus vectors 
were administered to the CNS of  neonatal mice, with an n of three for the two lentivirus 
vectors (refer to on page 53 section 2.8.1 above “Neonatal intracranial injections of viral 
vectors”). 
The brains from both sets of mice were collected 35 days’ post injection and 
immunohistochemistry was performed to determine the GFP expression profile. The results 
revealed that VSV-G pseudotyped pCCL-SFFV-GFP lentivirus vector showed a wide spread of 
GFP expression from the olfactory bulb, the cortex, the hippocampus and the cerebellum 
(Figure 14). Nevertheless, GFP expression was mainly situated around the injection site, 
targeting cells of an astrocytic morphology. However, the spread of lentivirus vector was not 
as extensive with VSV-G pseudotyped LTR1-SFFV-GFP (Figure 15). The GFP expression was 
restricted to the injection site and the expression was only visible within the olfactory bulb, 
the cortex and the hippocampus (Figure 15). The cells transduced by the LTR1 vector were of 
a neuronal morphology.  
As the titre of the VSV-G pseudotyped LTR1-SFFV-GFP lentivirus vector was a log lower that 
the VSV-G pseudotyped pCCL-SFFV-GFP, this could explain the different expression profiles. 
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The negative control shown in Figure 16, showed no GFP expression as no lentivirus vector 
was administered to these set of mice (n = 3).  
The results showed that the VSV-G pseudotyped pCCL-SFFV-GFP lentivirus vector showed a 
widespread expression of GFP within the CNS after a single unilateral intracranial injection. 
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Figure 14 - The transduction efficiency of VSV-G pseudotyped pCCL-SFFV-GFP lentivirus within the 
mouse CNS 
A GFP immunoperoxidase stain was conducted on the brain sections. VSV-G pseudotyped pCCL-SFFV-JDG, 
showed expression around the injection side (contralateral side). The spread was present within the 
olfactory bulbs (A), the prefrontal cortex (B), the hippocampus (C) and the cerebellum (D).  The whole 
brains sections were taken at x5 magnification and the close up images were taken at x20 magnification.  
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Figure 15 - The transduction spread of VSV-G pseudotyped LTR1-SFFV-GFP lentivirus vector within the mouse 
CNS 
An GFP immunoperoxidase stain was conducted to detect the cells transduced by the virus. VSV-G pseudotyped 
LTR1-SFFV-JDG, showed GFP expression around the injection side (contralateral side). The titre was a log lower 
than the pCCL-SFFV-GFP vector. The spread was present within the olfactory bulbs (A), the prefrontal cortex (B) 
and the hippocampus (C). However, no GFP expression was present within the cerebellum (D). The whole brains 
sections were taken at x5 magnification and the close up images were taken at x20 magnification. 
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Figure 16 – GFP immunoperoxidase stain on mice which did not receive an intracranial lentivirus 
vector injection 
An GFP immunoperoxidase stain was conducted on brain sections which did not receive an intracranial 
administration of lentivirus vector. This figure shows the following regions of the brain; the olfactory 
bulbs (A), the prefrontal cortex (B), the hippocampus (C) and the cerebellum (D). The whole brains 
sections were taken at x5 magnification and the close up images were taken at x20 magnification. 
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3.2.1 Determining the spread of VSV-G pseudotyped pLNT-SFFV-Luc-2A-GFP within the 
neonatal mouse brain 
 
Selected biosensors were cloned using Gateway cloning, as described within section 2.2 
“Gateway cloning” on page 37 above. The biosensors contained a luciferase and GFP reporter 
genes. As I have shown in the results section 3.2 “Validating neonatal intracranial injections 
of lentivirus vector”, the spread of VSV-G pseudotyped pCCL-SFFV-GFP lentivirus vector was 
quite extensive within the mouse CNS, with GFP expression extending from the olfactory bulb 
through to the cerebellum. Based on these premises I hypothesised that the VSV-G 
pseudotyped pLNT-SFFV-Luc-2A-GFP biosensor would achieve a similar GFP expression as 
the VSV-G pseudotyped pCCL-SFFV-GFP lentivirus vector within the mouse brain.  
I therefore began by administering the VSV-G pseudotyped pLNT-SFFV-Luc-2A-GFP biosensor 
to the neonatal brain with an n number of 3 (Section 2.8.1 “Neonatal intracranial injections 
of viral vectors” on page 53). The mice were sacrificed at day 35 of development and the brain 
tissues were harvested. The GFP expression was determined by immunohistochemistry. GFP 
expression present within the olfactory bulbs, there was a few neuronal cells transduced 
within the cortex, hippocampus and around the ventricle within the cerebellum (Figure 17). 
This showed that the spread of VSV-G pseudotyped pLNT-SFFV-Luc-2A-GFP biosensor within 
the mouse CNS was minimal compared to the VSV-G pseudotyped pCCL-SFFV-GFP lentivirus 
vector (Figure 14). Expression as limited to target cells of a neuronal morphology as compared 
to astrocytic cells as seen by the VSV-G pseudotyped pCCL-SFFV-GFP lentivirus vector. The 
presence of a 2A bicistronic linker may explain why the expression of GFP within the mouse 
CNS s not as extensive when compared to a standard lentivirus vector pCCL-SFFV-GFP.  
Although the GFP expression of the biosensor was not as great as the pCCL-SFFV-GFP 
lentivirus vector we still went on to use the lentivirus vector biosensors to produce somatic-
transgenic mice. This is because we were interested in the detecting the luciferase expression 
in live mice.  
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Figure 17 - GFP expression after a neonatal intracranial injection of VSV-G pseudotyped pLNT-SFFV-
Luc-2A-GFP 
The GFP expression was detected by immunoperoxidase stain on the brain sections which had been 
injected with pLNT-SFFV-luc-2A-GFP lentivirus vector. VSV-G pseudotyped pLNT-SFFV-JDG, showed 
neuronal transduction around the injection side (contralateral side). Expression was present within the 
olfactory bulbs (A), the prefrontal cortex (B) the hippocampus (C) and the cerebellum (D).  The whole 
brains sections were taken at x5 magnification and the close up images were taken at x20 
magnification. 
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3.3 Establishing somatic transgenesis within the CNS with the use of integrating 
lentivirus 
 
Previous work, conducted by my colleagues and I (Buckley et al. 2015), monitored long term 
NFκB transcription factor activity specifically in the liver after a single intravenous 
administration of a lentivirus biosensor. This allowed the generation of a liver specific somatic 
transgenic mouse.  
I hypothesised that long term somatic transgenesis could be achieved within the mouse CNS 
through a single intracranial administration of a constitutive promoter SFFV biosensor.  
In order to establish long term somatic transgenesis within the mouse CNS, I began by 
administering VSV-G or GP64 pseudotyped SFFV biosensor to neonatal mice (2.8.1 “Neonatal 
intracranial injections of viral vectors”, on page 53). The mice were imaged by whole body 
bioluminescence, shown in Figure 18. The quantification of the imaging was, achieved using 
Living Image® software and the values were plotted into a linear scatter graph. Both set of 
mice were imaged consciously for 20 days. The expression profile, shown in Figure 19, showed 
greater expression being from the VSV-G SFFV biosensor as this was the higher titred vector 
out of the two (VSV-G SFFV biosensor - 2×109 viral particles/mL, GP64 SFFV biosensor - 1×109 
viral particles/mL). The mice from both groups continued to show luciferase expression, 
therefore showing that long term somatic transgenesis within the mouse CNS using a SFFV 
biosensor could be achieved.  
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Figure 18 - Whole body bioluminescence imaging of mice which have received an intracranial injection of 
an VSV-G SFFV biosensor 
An VSV-G SFFV biosensor with a titre of 2×109 viral particles/mL were administered to new born mice via 
intracranial injections. This image shows mice which can be imaged consciously (A and B) and unconsciously 
(C). Image A is of an P7 mouse, image B is of an P23 mouse and image C is of an P35 mouse. The regions of 
interest (ROI) were measured using Living Image Software (Perkin Elmer, Coventry, UK) and expressed as 
photons per second per centimetre squared per steradian (photons/second-cm2/sr). 
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Figure 19 - Luciferase expression under the control of a constitutive promoter SFFV 
The two pseudotyped SFFV biosensor mice were imaged every 2 days for three weeks, with an n of 8 for VSV-G 
SFFV and n of 10 for GP64 SFFV biosensor. The VSV-G SFFV biosensor was a log higher in titre compared to the 
GP64 SFFV biosensor. This would explain the higher luciferase expression detected from the mice which received 
the VSV-G SFFV biosensor.  
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3.3.1 Establishing CNS somatic transgenesis with the use of different transcription 
binding elements and promoter biosensors 
 
As I was able to achieve long term somatic transgenesis up to three weeks within the mouse 
CNS with the use of a constitutively-expressed SFFV biosensor, I decided to replicate this using 
biosensors carrying varying transcription factor binding elements and promoters. I 
hypothesised that long term somatic transgenesis within the mouse CNS can be achieved 
with the use of VSV-G and GP64 GFAP, NFκB and STAT3 biosensors.  
The three main response elements and transcription factor binding elements which would be 
best suited for monitoring astrogliosis were GFAP, NFκB and STAT3 (Section “1.9 Role of 
astrocytes within the CNS” on page 32). Therefore, both VSV-G and GP64 pseudotyped 
lentivirus vector for each biosensor were produced. They all had titres values between 1-
4×109 viral particles/mL.  
A mouse truncated GFAP promoter was cloned into the lentiviral vector backbone by using 
gateway recombination (Section 2.2.6 “Cloning of the GFAP biosensor” on page 39).  
The mice which had received the GFAP biosensor enveloped with either VSV-G or GP64 were 
imaged over the course of development. The results of the VSV-G and GP64 GFAP biosensors 
are shown in Figure 20. These results reveal two different expression profiles from the two 
pseudotypes used, suggesting that they target different cell types within the CNS.  
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Figure 20 - Luciferase expression under the control of a mouse truncated GFAP promoter 
This graph shows luciferase expression measured from both the VSV-G and GP64 GFAP biosensor. The mice 
were imaged on day 7, 14, 21 and 47 (n=6 per biosensor). There were two expression profiles observed 
between the two pseudotypes of GFAP biosensors. This may be due to the fact that the VSV-G GFAP biosensor 
was a log higher in titre compared to the GP64 GFAP biosensor.  
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NFκB and STAT3 response elements were separately cloned into the lentivirus vector 
backbone using gateway recombination. Both VSV-G and GP64 pseudotyped NFκB and STAT3 
biosensor were administered intracranially to new-born mice and underwent whole body 
bioluminescence imaging every other day, each biosensor having an n of 6. The mice were 
also imaged consciously until day 53, after which the mice were imaged unconsciously until 
day 128. Imaging these mice daily until P14, allowed me to observe a peak of luciferase 
expression at P10 from mice which had received the VSV-G and GP64 STAT3 biosensor (Figure 
21; panel A). The peaks are further emphasized in the mean fold change in bioluminescence 
in panel B. A fold change in luciferase expression was calculated by finding the median from 
P3-5 (baseline triplets) readings and comparing them to the raw values obtained. Median is 
used as unlike the mean it is a robust measure of central tendency, thus the median won’t be 
affected by an outlier in the baseline triplets. 
To confirm whether this is what I was observing in my results, I decided to repeat the 
experiment to determine the P10 STAT3 peak. The peak was again shown by the GP64 and 
VSV-G STAT3 biosensors (Section 11.3 “Fold change in bioluminescence showing peak at P10 
with STAT3 biosensors” on page 156, Figure 56).  
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Figure 21 - A log scale plot illustrating the quantification of whole body bioluminescence imaging 
Panel A represents the raw data collected in a log scale from all four biosensors used. The black arrow 
represents the peaks at P10 for the STAT3 biosensors. Panel B shows the mean fold change in 
bioluminescence from each biosensor. The peak at P10 is further shown for both STAT3 biosensors in 
panel B.  
A 
B 
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To evaluate the biosensors, each mouse received an intraperitoneal injection of LPS 
(25mg/mL) at day 85 of age. LPS was used to induce an immune response and therefore 
generate an increase in luciferase expression. The mice were imaged at 4, 24, 48, 72 hours 
and a week before the stimulation, then at the same time once they had received LPS. This 
was to control for possibility of the frequency of imaging causing a change in the luciferase 
expression.  A single administration of LPS induced a marked up-regulation of luciferase 
activity in the brains of VSV-G NFκB mice 24 hours after receiving LPS. A slight increase of 
luciferase activity was observed in the VSV-G and GP64 STAT3 mice. However, a change of 
luciferase expression was not observed in the GP64 NFκB mice (Figure 22). When a Two-way 
ANOVA and a multiple comparison was conducted a significant difference was observed 
between the luciferase expression from day 85 to 86 and day 85 to 87 (P = 0.008) within the 
VSV-G NFκB mice. However, no significant different was observed with the other biosensors.  
The results revealed that only the VSV-G NFκB biosensing mice responded to LPS.  
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Figure 22 - Fold change of bioluminescence after mice received an IP injection of LPS 
The mice were injected with LPS at day 85 (n = 5 for each biosensor). The raw log data is shown in the top 
graph. A marked upregulation of luciferase expression within the brain was only observed in mice which had 
received the VSV-G NFκB biosensor, P = 0.008 (A). A slight increase of luciferase expression was observed in 
the VSV-G STAT3 and GP64 STAT3 mice (C and D). However, no change of luciferase expression was observed 
in the GP64 NFκB mice (B). A fold change was calculated by comparing the medians from days 60 to 63 to 
the raw values obtained. These graphs represent the means of the fold changes from day 80 to 130. Standard 
deviation error bars are also included in each graph. 
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3.4 Injection-associated inflammation 
 
Particular studies have shown efficient gene delivery through the use of lentivirus to the CNS 
and systemic organs by administering lentivirus vector to fetal mice (Waddington et al. 2003; 
Rahim et al. 2009). Mice which had received lentivirus vector at E16 did not show any adverse 
effects to vector (Rahim et al. 2009), therefore there was no evidence of reactive microglia 
and astrogliosis.  
However, adult intracranial injections to rodent brains have been shown to induce an 
inflammatory response (Wong et al. 2006), I hypothesised that the neonatal intracranial 
injections would not induce and inflammatory response and cause reactive microglia and 
astrogliosis.  
Neonatal mice received a lentiviral vector injection (VSV-G pLNT-SFFV-JDG; 2×109 viral 
particles/mL) at birth. Their brains were harvested at P35 and immunohistochemistry was 
performed to determine CD68 (microglial activation) and GFAP (astrogliosis) expression.  
As adult intracranial rat injections have shown to cause an inflammatory response around the 
needle track (Rahim et al. 2009) a positive control was used, where adult mice received an 
intracranial injection into the hippocampal region and the brains were harvested a week later, 
as positive (age matched) controls.  
The new-born neonatal mice which received an intracranial injection of the lentivirus vector 
showed no evidence of astrogliosis nor reactive microglia (Neonatal panel in Figure 23 and 
Figure 24). However, the adult injected mice showed astrogliosis and reactive microglia 
around the site of injection, shown in Figure 23 and Figure 24 (arrow). There was no evidence 
of astrogliosis and reactive microglia within the negative controls. 
These results reveal that administration of vectors at birth to the CNS causes neither an 
inflammatory response nor scarring.  
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Figure 23 - GFAP immunohistochemistry to mark scarring after intracranial injections 
New-born outbred CD1 mice (n = 3) which received an intraventricular injection of lentivirus, showed no 
evidence of glia scarring on either site of the brain. However, adult mice which received an intracranial 
injection showed astrogliosis around the injection site, shown by the arrow on the contralateral section. 
Astrogliosis was not observed in the negative control. All the tissues were harvested around 5 weeks of age. 
The whole brain section brains were taken at 5x magnification.  
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Figure 24 -CD68 immunohistochemistry to mark scarring after intracranial injections 
New-born outbred CD1 mice (n = 3) which received an intraventricular injection of lentivirus, showed no 
evidence of microglia reactivity on either side of the brain. However, adult mice which received an 
intracranial injection showed microglia reactivity around the needle track, shown by the arrow on the 
contralateral section. The negative control showed no evidence of reactive microglia. All the tissues were 
harvested around 6 weeks of age. The whole brain section brains were taken at 5x magnification.  
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3.5 Ex vivo luminometry on Somatic-transgenic brain tissue 
 
Somatic-transgenesis within the mouse CNS showed that the luciferase expression tended to 
decline over development and this is shown above on page 68, section 3.3 “Establishing 
somatic transgenesis within the CNS with the use of integrating lentivirus”. I hypothesised 
that the ossification of the mouse skull over development attenuates the photon emission.  
To test the hypothesis, mice received an intraventricular injection of the VSV-G SFFV 
biosensor at birth  and over the course of 5 weeks, every week three injected mice were 
imaged and then their brains were harvested and processed for ex vivo luminometry (page 
55, section 2.9 “Ex vivo Luminometry”). 
 
Figure 25 - Ex vivo luciferase expression vs. in vivo luciferase expression of the CNS 
There was a significant correlation between the in vivo and ex vivo luciferase expression. (P = 0.0003, R2 = 
0.5690). The luciferase expression was quantified from each mouse by whole body bioluminescence 
imaging. The brain tissues were collected and homogenised in order to conduct an ex vivo luciferase assay.  
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The results showed that the in vivo and the ex vivo luciferase expression correlated 
significantly (Figure 25). These results lead to the rejection of my hypothesis and showed that 
the skull does not attenuate the luciferase expression.  
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generation of brain damage mice models 
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4 Results II - Somatic-transgenesis and generation of brain damage mice 
models 
 
4.1 Establishing the HIE model within outbred CD1 mice 
 
The HIE rat model was first established in 1981, whereby animals received both ligation of the 
left carotid artery and exposure to 8% oxygen (Rice et al. 1981). This has been described in 
detail above on page 25 section 1.8.1“Hypoxic Ischemic Encephalopathy (HIE)”. 
The HIE mouse model has been established within Professor Henrik H Hagberg’s laboratory. I 
visited his laboratory to learn the surgical skills and technique in the context of 
bioluminescence imaging. I was taught how to induce the surgical model on day 7 post-natal 
C57BL/6J mice, which they use routinely (Albertsson et al. 2014).  
I hypothesised that the HIE mouse model would work with outbred CD1 mice, using the set 
up that we designed at UCL.   
As I had to set up the equipment from scratch at UCL, our surgical set up was quite different 
from the one which was used by Hagberg’s laboratory. The hypoxic chamber which we 
designed and produced at UCL with Dr. Simon N Waddington is shown in Figure 26.  
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Hagberg’s laboratory use C57BL/6J strain for this model, however I used a CD1 strain as white 
mice emit bioluminescence much greater than black mice (Wiles et al. 2009). Therefore, as 
we were using a different strain to conduct the HIE surgery, we had to optimise and determine 
which exposure time of hypoxia would balance damage and death. The other equipment 
which was different to Hagberg’s laboratory was that we could not change the percentage of 
oxygen and therefore had to stick to exposing the mice to 10% oxygen balanced with nitrogen.  
I began by ligating the carotid artery of P7 mice and then exposing the mice to either 60, 70, 
80 or 90 minutes of 10% oxygen balanced with nitrogen at 36°C. The brains were harvested 
48 hours’ post-surgery and CNS infarct was blind marked. The brains were either classified as 
normal, mild, moderate and severe, with number 1 being normal and 4 being severe, 
examples of these are shown in Figure 27.  The blind marking revealed that 90 minute 
exposure time showed the greatest CNS lesion, shown in Figure 28. The reason why I did not 
Figure 26 - The hypoxic chamber designed and set up at UCL 
The hypoxic chamber was designed by using a plastic container with compartments set up inside 
it to place each individual mouse in. The chamber contains a temperature controller which is set 
at 36°C. The flow of 10% oxygen balanced with nitrogen was fed into the chamber using the flow 
rate controller and the rubber tubbing.  
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exceed 90 minutes’ exposure to 10% oxygen was because the number of deaths started to 
increase as exposure time increased and so to avoid further unacceptable death I stopped at 
90 minutes.  
I therefore chose this exposure time to validate the disease model within outbred CD1 mice.  
 
 
 
 
 
 
 
 
 
 
 
Figure 27 - Injury scores after P7 outbred CD1 mice received hypoxic-ischemic surgery 
Brains were collected 48 hours after surgery. Pathology ranges from, normal - where injury is not 
visible. Mild –brain tissue on the right side has gone white in colour showing that damage. Moderate 
– tissue from the right side of the brain is missing. Severe – the right hemisphere is deformed with 
extensive tissue loss. 
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Surgery was conducted on mice at P7 and brains were harvested at either 48 hours or 7 days’ 
post-surgery. Immunohistochemistry was carried and staining for reactive microglia (CD68) 
and astrogliosis (GFAP) was conducted to determine the presence of CNS damage and to 
monitor the variability of the model.  
I also conducted a Nissl stain (Figure 31 and Figure 34). A Nissl stain shows rough endoplasmic 
reticulum, ribosomal RNA and DNA (Gersh & Bodian 1943). Nissl bodies are seen within the 
cell body of the neurons and they disappear in response to ischemia due to neuronal cell 
death.   
Figure 28 - Blind marking score from different exposure times to 10% oxygen balanced with nitrogen 
4 groups of 10 mice per exposure time (in minutes) underwent surgery. The brains were harvested 48 
hours after surgery. Each brain was given a blind mark score. Mice which died were given a score of 5, 
shown in red. 90 minutes of exposure time revealed to give the most severe brain tissue pathology 
and variability.  
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The results showed that the severe, moderate and mild brains which were collected at both 
48 hours and 7 days post-surgery contained reactive microglia which was predominately seen 
within the HIE lesioned right hemisphere of the cortex and the hippocampus (Figure 29 and 
Figure 32). In contrast, the contralateral side was absent of reactive microglia. The same was 
observed with the GFAP stain which showed reactive astrogliosis within the right damaged 
hemisphere of the severe, moderate and mild cortex and hippocampus (Figure 30 and Figure 
33). Again this was absent within the contralateral cortex and hippocampus. The 
histopathology demonstrated that a higher percentage of Nissl bodies were observed within 
the normal brains collected at both time points and the Nissl bodies were less obvious within 
the severe brains (Figure 31 and Figure 34).  
To conclude these results confirmed that we effectively generated a novel CD1 based HIE 
mouse model and that the brains exhibited a spectrum of injury which was consistent with 
previous publication (Wang et al. 2004; Wang et al. 2010).  
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Figure 29 - Immunohistochemistry showing a CD68 stain for HIE brains harvested 48 hours after surgery 
The diagram illustrates the four types of injury score achieved after surgery (Figure 27 - "Injury scores after P7 
outbred CD1 mice received hypoxic-ischemic surgery”, page 85). After surgery damage is mostly seen within 
the cortex and the hippocampus. The upper section in each panel is a coronal section at the cortex and the 
second is of the hippocampus. Severe is shown in panel A, where most of the right hemisphere is damaged. 
Panel B represents moderate damage, panel C with mild and panel D with normal morphology of the HIE mouse 
brain. The section images were taken at 5x and the higher magnification images were taken at 40x 
magnification. 
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Figure 30 - Immunohistochemistry showing a GFAP stain for HIE brains harvested 48 hours after 
surgery 
The diagram illustrates the four types of injury score achieved after surgery. The right hemisphere 
represents the HIE damaged side of the brain. The upper section in each panel is a coronal section at 
the cortex and the second is of the hippocampus. The sections were stained for GFAP. The section 
images were taken at 5x and the higher magnification images were taken at 40x magnification. 
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Figure 31 - Nissl stain for HIE brains harvested 48 hours after surgery 
Nissl stain is shown for severe, moderate, mild and normal HIE brains collected 48 hours’ post-surgery. The 
right hemisphere is the lesioned side of the brain. Fewer Nissl bodies are seen within the severe and 
moderate HIE right hemisphere brains. The upper section in each panel is a coronal section at the cortex 
and the second is of the hippocampus. The brain section images were taken at 5x and high magnification 
images were taken at 40x magnification. 
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Figure 32 - Immunohistochemistry showing a CD68 stain for HIE brains harvested 7 days after surgery 
The upper section in each panel is a coronal section at the cortex and the second is of the hippocampus. 
After surgery damage is mostly seen within the cortex and the hippocampus, this is mainly observed within 
the right hemisphere. The brain section images were taken at 5x magnification and the higher magnification 
images were taken at 40x.  
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Figure 33 - Immunohistochemistry showing a GFAP stain for HIE brains harvested 7 days after 
surgery 
The upper section in each panel is a coronal section at the cortex and the second is of the hippocampus. 
Greater GFAP expression is seen within the severe, moderate cortex and hippocampus of the right 
hemisphere. The brain sections were taken at 5x magnification and the higher magnification images 
were taken at 40x.  
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Figure 34 - Nissl stain for HIE brains 7days after surgery 
Nissl stain is shown for the four types of injury score conducted in this project. The upper section in each 
panel is a coronal section at the cortex and the second is of the hippocampus. Fewer Nissl bodies are seen 
within the severe and moderate HIE right hemisphere brains. The images of the brain sections are taken 
at 5x magnification and the higher magnification images are taken at 40x.  
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4.2 Lentiviral biosensors applied to the HIE model  
 
Once the HIE model had been validated and we had established long term somatic-
transgenesis within the CNS of outbred CD1 mice, I wanted to test whether the biosensors 
would respond to the disease manifesting within the HIE mouse model. 
4.2.1 GP64 pseudotyped biosensors administered to HIE mice 
 
As one central aims of my thesis was to monitor astrogliosis within the HIE mouse model, and 
previous work has shown that adult intracranial injection of GP64 pseudotyped lentiviral 
vector targets astrocytic cells (Rahim et al. 2009), I therefore began by testing GP64 
pseudotyped NFκB, SFFV, GFAP and STAT3 biosensors. 
The GP64 pseudotyped lentivirus vectors were administered intracranially to new-born 
outbred CD1 mice. The mice were imaged every day until P7, when the mice received carotid 
artery ligation and hypoxia (2.8.5 “Rice-Vanucci HIE model” on page 54). The mice were split 
into two groups by random blinded selection. The sham controls received an incision at the 
neck and this opening was then closed again and the pups were returned to their dam. 24 
hours after surgery the mice were then imaged by conscious whole body bioluminescence 
until developmental day 21, when all the mice were perfused and their brain tissues were 
harvested for free floating immunohistochemistry.  The mice were weighed daily as it has 
been shown CNS damage is inversely correlated with body weight. This is because mice with 
the severely damaged CNS are not able to feed as well as mice which have been subjected to 
less extent of damaged or no damaged at all (Bellot et al. 2014).  
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4.2.1.1 GP64 NFκB biosensor  
 
The GP64 NFκB biosensor was chosen as previous work has shown that the transcription 
factor NFκB is activated in astrocytes in response to CNS lesion (Acarin et al. 2000). I 
hypothesised that the mice which have received GP64 NFκB biosensor their luciferase 
expression 24 hours after surgery would correlate with the weight of the mice 7 days after 
surgery.  
An injury score was obtained at the end of the experiment when the brain tissues were 
harvested. Each brain was given an injury score of 1 to 4, 1 being normal brain morphology 
and 4 having a severe morphology. This score was plotted against the fold change in luciferase 
expression 24 hours’ post-surgery. The HIE mice that died during the experiment were given 
an injury score of 5. For the first GP64 NFκB experiment, there was a significant negative 
correlation between the injury score and the bioluminescence 24 hours after surgery, P = 
0.0001 (Figure 35). A significant correlation was not observed again when the experiment was 
repeated (P = 0.156), shown in Figure 36.  
A significant positive correlation was observed with the fold change of luciferase expression 
24 hours after surgery and the weight of the mice 7 days’ post-surgery, with a P value of 
0.0007 (Figure 35). However, when the experiment was repeated there was no significant 
correlation (Figure 36). For both experiment’s there was no significant correlation between 
the fold change of luciferase expression for the HIE and sham mice (Figure 35 and Figure 36).  
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Figure 35 - Fold change of Bioluminescence, injury score and weight quantified from mice which received 
the GP64 NFκB biosensor and underwent HIE surgery 
Panel A shows the fold change of bioluminescence from the HIE mice vs the Sham mice, there was no 
significant difference (P = 0.909). Standard error mean bars plotted for both HIE and sham mice. The blind 
marking injury score was plotted against the fold change of bioluminescence 24 hours after surgery, there 
was a significant correlation between the two (P = 0.0001). The HIE mice which died during the course of the 
experiment were given an injury score of 5.  The fold change in luciferase expression 24 hours after surgery 
vs the weight 7 days on from surgery had a significant correlation with P = 0.0007, shown in graph C. Total 
mice subjected to surgery; HIE mice = 15, Sham mice = 5. 
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Figure 36 - Fold change of Bioluminescence, injury score and weight quantified from mice which received the 
GP64 NFκB biosensor and underwent HIE surgery  
Panel A shows the fold change of bioluminescence from the HIE mice vs the Sham mice, (not significant P = 0.150). 
Standard error mean bars plotted for both HIE and sham mice. The blind marking injury score was plotted against 
the fold change of luciferase expression, there was no significant correlation between the two (P = 0.156). The HIE 
mice which died over the course of the experiment were given an injury score of 5. The fold change in luciferase 
expression 24 hours after surgery vs the weight 7 days on from surgery showed no significant correlation (P = 
0.461), shown in panel C. Total mice subjected to surgery; HIE mice = 20, Sham mice = 10.  
 
Results II - Somatic-transgenesis and generation of brain damage mice models | Page 98 
4.2.1.2 GP64 SFFV biosensor 
 
As the two GP64 NFκB HIE experiments revealed inconsistent results, I decided to use a 
biosensor with a constitutive promoter, SFFV. In order to eliminate the transcription factor 
response or to investigate the inconsistency further I used a constitutive promoter, SFFV.  
I hypothesised that the mice which have received GP64 SFFV biosensor their luciferase 
expression 24 hours after surgery would not correlate with the weight of the mice 7 days 
after surgery.  
Unexpectedly the GP64 SFFV biosensor experiment revealed a significant negative correlation 
between the fold change of bioluminescence 24 hours post-surgery and the weight of the HIE 
mice 7 days after surgery, with a P value of 0.023 (Figure 37). However, there was no 
significant difference between the fold change of luciferase expression of the HIE and the 
sham mice. There also was no significant correlation between the injury score and the fold 
change of bioluminescence 24 hours after surgery (Figure 37).  
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Figure 37 - Fold change of Bioluminescence, injury score and weight quantified from mice which received 
the GP64 SFFV biosensor and underwent HIE surgery 
Panel A shows the fold change of bioluminescence from the HIE mice vs the Sham mice, (not significant P = 
0.879). Standard error mean bars plotted for both HIE and sham mice. The blind marking injury score was 
plotted against the fold change of luciferase expression 24 hours after surgery, there was no significant 
correlation between the two (P = 0.096). The fold change in luciferase expression 24 hours after surgery vs the 
weight 7 days on from surgery had a significant correlation (P = 0.023), shown in panel C. Total number of 
mice which underwent surgery; HIE mice = 15, Sham mice = 10.  
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4.2.1.3 GP64 GFAP biosensor  
 
A hallmark of astrogliosis is the up-regulation of the intermediate filament, GFAP (Järlestedt 
et al. 2010). Serum GFAP has been shown to increase in severe neonates with HIE and its 
levels have shown to elevated in moderate to severe HIE (Chalak et al. 2014).  In order to test 
the upregulation of GFAP within astrocytes in response to HIE, I decided to use the GP64 GFAP 
biosensor within the HIE mice. I therefore hypothesised that there would be an increase in 
luciferase expression 24 hours after surgery and this would correlate with the weight of the 
mice 7 days post-surgery.  
The GP64 GFAP biosensor experiment showed a significant negative correlation between the 
injury score and the fold change in luciferase expression 24 hours after surgery (P = 0.002), 
shown in Figure 38. However, no correlation was detected between the HIE and sham fold 
change in luciferase expression and nor between the Δ bioluminescence and weight 7 days 
post-surgery (Figure 38).  
 
 
 
 
 
 
 
 
 
 
 
 
Results II - Somatic-transgenesis and generation of brain damage mice models | Page 101 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 38 - Fold change of Bioluminescence, injury score and weight quantified from mice which received 
the GP64 GFAP biosensor and underwent HIE surgery 
Panel A shows the fold change of bioluminescence from the HIE mice vs the Sham mice, (not significant P = 
0.778). Standard error mean bars plotted for both HIE and sham mice. The blind marking injury score was 
plotted against the fold change of luciferase expression 24 hours after surgery, there was a significant 
correlation between the two (P = 0.002). The fold change in luciferase expression 24 hours after surgery vs 
the weight 7 days on from surgery showed no significant correlation (P = 0.226), shown in panel C. Total 
number of mice which underwent surgery; HIE mice = 10, Sham mice = 3. One of the HIE mice died before day 
21.  
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4.2.1.4 GP64 STAT3 biosensor 
 
STAT3 transcription factor has been shown to be induced in response to HIE specifically within 
astrocytes (Shrivastava et al. 2013). Other studies have also shown that removing STAT3 from 
neurons and astrocytes reduced inflammation in response to HIE (Hristova et al. 2015). To 
monitor STAT3 activation in astrocytes during HIE I hypothesised that luciferase expression 
under the control of a STAT3 response element would increase 24 hours after HIE surgery.  
The GP64 STAT3 biosensor experiment did not show any significant correlation in all three 
comparisons of data, shown in Figure 39.  
 
To conclude only the first GP64 NFκB and GP64 SFFV experiments supported my hypothesis 
that biosensors could be used to predict HIE. The correlations between all the comparisons in 
all these experiments are summarised in Table 1.  
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Figure 39 -Fold change of Bioluminescence, injury score and weight quantified from mice which received 
the GP64 GFAP biosensor and underwent HIE surgery 
Panel A shows the fold change of bioluminescence from the HIE mice vs the Sham mice, (not significant P = 
0.490). Standard error mean bars plotted for both HIE and sham mice. The blind marking injury score was 
plotted against the fold change of bioluminescence 24 hours’ post-surgery, there was no significant 
correlation between the two (P = 0.996). The fold change in luciferase expression 24 hours after surgery vs the 
weight 7 days on from surgery showed no significant correlation (P = 0.070), shown in panel C. Total number 
of mice which underwent surgery; HIE mice = 10, Sham mice = 3. 
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Experiment 
 
The difference 
between Δ 
Bioluminescence of 
HIE vs. Sham mice 
(2-way ANOVA, 
with repeated 
measures) 
Injury score vs. Δ 
Bioluminescence 24 
hours after surgery 
 
Δ Bioluminescence 
24 hours after 
surgery vs. weight 7 
days after surgery  
 
GP64 NFκB 
HIE mice = 15, Sham 
mice = 5 
No difference, P = 
0.909 
 
Significant positive 
correlation, P = 
0.007 
Significant negative 
correlation, P = 
0.0001 
 
GP64 NFκB 
(Experiment 2)     
HIE mice = 20, Sham 
mice = 10 
No difference, P = 
0.150 
 
No correlation, P = 
0.156 
 
No correlation, P = 
0.461 
GP64 SFFV 
HIE mice = 15, Sham 
mice = 10 
No difference, P = 
0.879 
 
No correlation, P = 
0.096 
 
Significant negative 
correlation, P = 
0.023 
GP64 GFAP 
HIE mice = 10, Sham 
mice = 3 
No difference, P = 
0.778 
 
Significant negative 
correlation, P = 
0.002 
No correlation, P = 
0.226 
GP64 STAT3 
HIE mice = 10, Sham 
mice = 3 
No difference, P = 
0.490 
 
No correlation, P = 
0.996 
 
No correlation, P = 
0.070 
 
 
Table 1 - A summary of the results achieved with the use of GP64 pseudotyped lentivirus 
vectors in HIE mice 
The results are summarised with the use of the GP64 biosensors in the table above. The three 
comparisons of data; The difference between Δ Bioluminescence of HIE vs. Sham mice, Injury 
score vs. Δ Bioluminescence 24 hours after surgery and Δ Bioluminescence 24 hours after 
surgery vs. weight 7 days after surgery. The significant results are shown in bold.  
 
 
Results II - Somatic-transgenesis and generation of brain damage mice models | Page 105 
4.2.2 VSV-G pseudotyped biosensors administered to HIE mice 
 
The VSV-G pseudotyped lentivirus has shown to target neuronal cells within the CNS (Azzouz 
et al. 2004). Therefore, the aim of this study was to monitor whether the biosensors that 
targeted neuronal cells would respond to the damaged CNS caused by the hypoxic-ischaemic 
surgery. The two biosensors which were chosen to test this aim was VSV-G NFκB and VSV-G 
SFFV.  
 
4.2.2.1 VSV-G NFκB biosensor  
 
The transcription factor NFκB has shown to be expressed within neurons (Kaltschmidt & 
Kaltschmidt 2009), this lead on to the hypothesis that luciferase expression under the control 
of an NFκB response element would be elevated 24 hours after surgery and this would 
correlate with the weight of the mice 7 days post-surgery.  
The VSV-G NFκB biosensor experiment failed to show any significant correlation between the 
three relationships examined in this study; difference between Δ Bioluminescence of HIE vs. 
Sham mice, Injury score vs. Δ Bioluminescence 24 hours after surgery and Δ Bioluminescence 
24 hours after surgery vs. weight 7 days after surgery (Figure 40).  
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Figure 40 -Fold change of Bioluminescence, injury score and weight quantified from mice which received 
the VSV-G NFκB biosensor and underwent HIE surgery 
Panel A shows the fold change of bioluminescence from the HIE mice vs the Sham mice, (not significant P = 
0.533). Standard error mean bars plotted for both HIE and sham mice. The blind marking injury score was 
plotted against the fold change in luciferase expression 24 hours after surgery, there was no significant 
correlation between the two (P = 0.1601). The fold change in luciferase expression 24 hours after surgery vs 
the weight 7 days on from surgery showed no significant correlation (P = 0.480), shown in panel C. HIE mice 
= 12, Sham mice = 3. 
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4.2.2.2 VSV-G SFFV biosensor  
 
The VSV-G SFFV biosensor was chosen as it contains a constitutive promoter as this eliminates 
the transcription factor binding element of the lentiviral vector. 
I hypothesised that the luciferase expression under the control of SFFV would not be 
upregulated 24 hours after surgery and this would not correlate with the weight of the mice 
7 days’ post-surgery.  
The VSV-G SFFV experiment demonstrated a significant negative correlation between the 
injury score and the fold change in bioluminescence 24 hours post-surgery, with a P value of 
0.0002 (Figure 41). Similar to the VSV-G NFκB biosensor experiment there were no significant 
difference between HIE and the sham mice Δ bioluminescence and the fold change in 
luciferase expression 24 hours after surgery and the weight of the HIE mice 7 days post-
surgery (Figure 41).  
The results showed that the VSV-G pseudotyped biosensors used within the HIE mice failed 
to show a significant correlation between the fold change in luciferase expression 24 hours 
after surgery and the weight of the HIE mice 7 days’ post-surgery. The results are summarised 
in Table 2. 
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Figure 41  - Fold change of Bioluminescence, injury score and weight quantified from mice which received 
the VSV-G SFFV biosensor and underwent HIE surgery. 
Panel A shows the fold change of bioluminescence from the HIE mice vs the Sham mice, (not significant P = 
0.991). Standard error mean bars plotted for both HIE and sham mice. The blind marking injury score was 
plotted against the fold change in luciferase expression 24 hours after surgery, there was a significant 
correlation between the two (P = 0.0002). The fold change in luciferase expression 24 hours after surgery vs 
the weight 7 days on from surgery showed no significant correlation (P = 0.081), shown in panel C. Number 
mice which underwent surgery; HIE mice = 12, Sham mice = 9. 
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Experiment 
 
The difference 
between Δ 
Bioluminescence of 
HIE vs. Sham mice 
(Two-way ANOVA, 
repeated measures) 
Injury score vs. Δ 
Bioluminescence 24 
hours after surgery 
 
Δ Bioluminescence 
24 hours after 
surgery vs. weight 7 
days after surgery  
 
VSV-G NFκB 
HIE mice = 12, Sham 
mice = 3 
No difference, P = 
0.533 
 
No correlation, P = 
0.1601 
 
No correlation, P = 
0.480 
 
VSV-G SFFV 
HIE mice = 12, Sham 
mice = 9 
No difference, P = 
0.991 
 
Significant negative 
correlation, P = 
0.0002 
 
No correlation, P = 
0.081 
 
 
Table 2 - A summary of the results obtained with VSV-G enveloped lentivirus vectors 
within HIE mice 
The three comparisons of data are summarised; The difference between Δ Bioluminescence of 
HIE vs. Sham mice, Injury score vs. Δ Bioluminescence 24 hours after surgery and Δ 
Bioluminescence 24 hours after surgery vs. weight 7 days after surgery. The significant results 
are shown in bold. The significant correlations are shown in bold.  
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4.3 Type II Gaucher disease model 
 
The previous chapter, describes the failure of lentivirus vector biosensors to consistently 
predict disease pathology within the HIE mouse model. I therefore decided to use a mouse 
model of early onset neurodegeneration, Type II Gaucher disease (GD).  
Type II Gaucher disease is a lethal neurological disease which manifests during gestation and 
results in death around 2 years of age (Orvisky et al. 2000). GD is an inherited metabolic 
disease caused by β-glucocerebrosidase deficiency (Guggenbuhl et al. 2008). Affected mice 
die at P12, and they have been characterised with extensive neuronal loss (Enquist et al. 
2007).  
I hypothesised that the VSV-G SFFV biosensor would monitor the extent of neuronal loss 
within the knockout GS model.  
To investigate whether the biosensors would respond to the neurological disease present 
within the GD mouse model, mice received an intracranial injection of the VSV-G SFFV 
biosensor at birth.  
The mice were imaged every day until P15. From the quantified luciferase data I observed 
that there was no differential expression seen from either the wild-type and heterozygote GD 
mice (Figure 42).  
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Figure 42 - The luciferase expression quantified from VSV-G SFFV biosensor administered to GD mice 
The mice were imaged every day from day 2 to day 15 of development by whole body bioluminescence 
imaging. The wild type mice are shown in red and the heterozygote mice are shown in yellow. 13 mice 
were administered the VSV-G SFFV biosensor. 
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5 Results III - GFAP biosensor responds in liver fibrosis 
 
As there was no consistent biosensor response in the two neurological disease models, I 
applied my GFAP biosensor to a liver fibrosis model. The liver fibrosis model has previously 
shown to exhibit an up-regulation of GFAP within liver hepatic stellate cells and it has been 
shown to play an important role with in hepatic fibrogenesis  (Tennakoon et al. 2013). 
Previous studies have also shown that lentivirus vectors carrying a GFAP promoter driving an 
luciferase reporter gene were able to transduce and show upregulated reporter gene 
expression in hepatic stellate cells within a mouse liver (Yuan-Yuan et al. 1998).  
I hypothesised that the VSV-G GFAP biosensor would induce an upregulation of luciferase 
expression after the induction of liver fibrosis within the mouse model.  
The mice received an intravenous injection of the VSV-G GFAP biosensor at birth (Section 
2.8.2 “Neonatal intravenous injections of viral vectors” on page 53). The bile duct ligation was 
performed at day 45 of development and the mice were imaged 72 hours’ post-surgery. The 
results showed that there was a significant difference in the luciferase expression between 
the bile duct mice and the sham controls, as shown in Figure 43.  
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Figure 43 - Fold change mean of luciferase expression post bile duct ligation 
Whole body bioluminescence imaging was taken from these mice pre and post bile duct ligation. The mice 
which received the surgery showed a significant increase of luciferase expression 72 hours after surgery 
compared to the sham controls.  
 
Results III - GFAP biosensor responds in liver fibrosis | Page 115 
 
 
 
 
 
 
 
Results IV - GP64 lentivirus targets cells of the 
CNS 
 
 
 
 
 
 
 
 
 
Results IV - GP64 lentivirus targets cells of the CNS | Page 116 
6 Results IV - GP64 lentivirus targets cells of the CNS  
 
The biosensors failed to respond to the two CNS disease models, however the VSV-G GFAP 
biosensor worked within the liver fibrosis model. I decided to re-examine the underlying 
assumption that GP64 pseudotyped lentiviral vector targets GFAP positive astrocyte cells. I 
therefore revisited what cell types were targeted within the CNS by the two pseudotypes of 
lentiviral vectors, used in this study; VSV-G and GP64.  
 
6.1 CNS targeted by GP64 SFFV biosensor  
 
I hypothesised that the GP64 pseudotyped lentiviral vectors were targeting neuronal and 
astrocytic cells.  
To test the hypothesis, I injected mice by intracranial administration with GP64 SFFV 
biosensor to new-born mice. Their brains were harvested at day 35.  
To determine the cell types that were being targeted by the GP64 pseudotyped lentivirus with 
in the CNS, I conduced a fluorescent immunohistochemistry. Anti-GFP antibody was used to 
detect the cells transduced by the vector and was co-strained with antibodies for the 
following proteins; GFAP, S100β, glutamate synthase, Iba-1 and NeuN. GFAP, S100β, 
glutamate synthase are astrocytic markers, Iba-1 is a microglia marker and NeuN stains for 
neurons.  
Injection of GP64-SFFV vector, resulted in very few cells that were transduced within the CNS 
that marked for astrocytic specific proteins, as shown in Figure 44 . Also, there was neither 
Iba-1 nor NeuN co-localisation achieved. The majority of the cells transduced by the GP64 
pseudotyped SFFV biosensor showed an astrocytic morphology however they remained 
unidentified by classic astrocytic markers.  
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Figure 44 - Fluorescent immunohistochemistry on GP64 SSFV biosensor transduced brains 
GFP was co-stained with Iba-1, S100β, GFAP, glutamate synthase and NeuN. S100β, GFAP, glutamate synthase 
co-stained with GFP, this is shown by the yellow cells in the merge column. However, Iba-1 and NeuN failed to 
co-stain. The DAPI stains for nuclei. All the images were taken at x40 magnification.  
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6.2 CNS targeted by VSV-G SFFV biosensor  
 
To confirm that VSV-G pseudotyped lentiviral vectors targeted neuronal cells within the CNS 
(Wong et al. 2006; Rahim et al. 2009), I decided to conduct fluorescent 
immunohistochemistry, where GFP would be co-stained with neuronal and astrocytic 
markers. I hypothesised that the VSV-G pseudotyped lentiviral vectors were targeting 
neuronal cells. 
I injected mice by intracranial administration with VSV-G SFFV biosensor to new-born out bred 
CD1 mice. The brains of these mice were harvested at day 35.  
Anti-GFP antibody was used to detect the cells transduced by the vector and this antibody 
was co-stained with the following proteins; NeuN, GFAP, S100β and glutamate synthase. 
VSV-G pseudotyped SFFV biosensor showed co-localisation between GFP and NeuN, however 
no co-localisation was observed with the astrocytic marker proteins (Figure 45). The results 
confirmed that the VSV-G pseudotyped SFFV biosensor targets cells of a neuronal markers. 
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Figure 45 - Fluorescent immunohistochemistry on VSV-G SFFV biosensor transduced brains. 
GFP was co-stained with NeuN, GFAP, Glutamine Synthase and S100β. NeuN co-stained with GFP, this is shown by 
the yellow cells in the merge column. However, GFP failed to co-stain with GFAP, Glutamine Synthase and S100β. 
The DAPI stains for nuclei. The images were taken at x40 magnification.  
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7 Results V – Lentivirus pseudotypes transduce primary neurons and glia 
 
The fluorescent immunohistochemistry carried out on brain tissues that were injected with 
either GP64 or VSV-G pseudotyped SFFV biosensors, revealed that the GP64 SFFV biosensor 
was targeting cells which did not co-localise with astrocytic specific proteins. These findings 
did not correlate with previous observations that GP64 pseudotyped lentiviral vectors target 
astrocytic cells within the mouse CNS (Rahim et al. 2009). 
To understand why the biosensors did not respond to the neurological disease models used 
within my work and further my understanding on the type of cells being targeted by the two 
lentiviral pseudotypes I decided to transfect primary neuronal and glial cultures with the 
biosensors used in this thesis.  
 
7.1 Transduction of neuronal and glial cells with GP64 biosensors  
 
As the in vivo data revealed occasional astrocytic cells being transduced by GP64 pseudotyped 
lentivirus I hypothesised that the GP64 enveloped biosensors could transduce glial cells in 
vitro. 
I compared the transduction efficiency in neuronal and glial cells. These cells were extracted 
from neonatal mice brains by using MACS separation (2.6.1 “Neuronal and glia cell 
separation” on page 51). The following biosensors were used to transduced primary neuronal 
and glia cultures; GP64 NFκB, GP64 GFAP and GP64 STAT3 (2.6.2 “Lentiviral transduction of 
neuronal and glia primary cell lines” on page 51). After 72 hours of transduction with the 
biosensors, the cells were lysed and a luciferase assay was conducted.  
GP64 GFAP and STAT3 biosensors showed a significant luciferase expression within the glia 
cultures compared to the neuronal cultures (Figure 46). Surprisingly, GP64 NFκB biosensor 
resulted in strong luciferase expression in neuronal cells not glia (not significant).  
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Figure 46 - Primary Neuronal and Glia cultures transduced by either GP64 NFκB, GP64 GFAP or GP64 STAT3 
biosensor 
The virus added to the cells for 72 hours, after which the cells were lysed for a luciferase assay. There was a 
significant difference in the luciferase expression observed within the glia cells compared to the neuronal cells 
when the GP64 GFAP and STAT3 biosensor was used. This experiment was repeated three times. 
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7.2 Transduction of neuronal cells with VSV-G NFκB biosensors  
 
Within my thesis I have confirmed that the VSV-G enveloped lentivirus vector transduces 
neuronal cells in vivo. The aim of this study was to validate these findings in vitro.  I therefore 
hypothesised that primary neuronal cells transduced with VSV-G NFκB biosensor would 
express more luciferase than glial cells.  
Neuronal and glial cells were extracted from neonatal mice brains by using MACS separation 
(2.6.1 “Neuronal and glia cell separation” on page 51). The VSV-G  NFκB biosensor was used 
to transduced primary neuronal and glia cultures; (2.6.2 “Lentiviral transduction of neuronal 
and glia primary cell lines” on page 51). After 72 hours of transduction with the biosensor, the 
cells were lysed and a luciferase assay was conducted.  
The results showed that the luciferase expression within the primary neuronal cells was 
significantly greater (P<0.0001) than the glia cells transduced with the VSV-G NFκB biosensor, 
shown in Figure 47.  
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The overall results showed that the both pseudotypes of lentiviral vectors transduced primary 
mouse neuronal and glia cells. Where GP64 NFκB targets neurons and the other GP64 
pseudotyped lentivirus vectors don’t. The VSV-G NFκB biosensor targets neuronal cells 
greater than glia cells.  
 
 
 
 
 
 
 
 
Figure 47 - Primary mouse neuronal and glia cells transduced with VSV-G NFκB biosensors 
The primary neuronal cells revealed a significantly greater expression of luciferase compared to the glia 
culture, 72 hours after transfection of the virus to cells. This experiment was repeated three times.  
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8 Results VI – CNS Somatic transgenesis with integration defective 
lentivirus 
 
The previous chapter showed that long term somatic transgenesis can be achieved with the 
use of a single administration of an integrating lentivirus vector (3.3 “Establishing somatic 
transgenesis within the CNS with the use of integrating lentivirus” on page 68). I have also 
shown that a minimal response to LPS was observed within the CNS of mice which had 
received the VSV-G NFκB biosensor (Figure 22 - Fold change of bioluminescence after mice 
received an IP injection of LPS” on page 76). I speculated that luciferase expression from 
integrated vector particles might be subject to upregulation by flanking genomic enhancer 
sequences and cause high background expression. This might account for the insensitivity of 
the biosensors response to LPS. The aim of the study was to monitor whether we would 
achieve a better response to LPS with the use of a IDLV episomal lentivirus vector. 
I hypothesised that long term somatic transgenesis can be achieved within the mouse CNS 
after a single intracranial administration of an IDLV VSV-G NFκB biosensor and that a 
response to LPS could be measured.  
I began by preparing VSV-G enveloped integrating and IDLV NFκB biosensor. The lentivirus 
vectors had a titre matched value of 1×109 viral particles/mL, determined by p24 assay. The 
biosensors were administered to new-born mice. In total 5 P1 mice were injected with either 
biosensor. The mice were imaged every other day until P49. Figure 48 represents the fold 
change of bioluminescence. Mice received an IP injection of LPS (25mg/mL) at day 42 
(represented by the red arrow on Figure 48). The results revealed that the VSV-G IDLV NFκB 
biosensor group responded to LPS but this did not reach statistical significance. I decided to 
repeat this experiment to investigate whether I would achieve the same result.  
The experiment was repeated with titre matched vector. A total of 6 mice were injected for 
each biosensor. To attempt to induce a significant response to LPS within the CNS mice 
received an IP injection of LPS earlier than the previous experiment, at P14. This is because it 
has been shown that LPS exerts an effect on LPS when administered early in life (Rocha-
Ferreira et al. 2015). The results revealed that the IDLV biosensor responded to LPS 
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significantly greater that the integrating biosensor (P = 0.025), with an up-regulation of 
luciferase expression 24 hours after receiving LPS (Figure 49).  
To conclude I was able to achieve somatic transgenesis with both integrating and integration 
defective lentivirus and show that the IDLV VSV-G NFκB biosensors responds better to LPS 
that the integrating biosensor.  
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Figure 48 - Fold change of luciferase expression from mice which have received integrating and IDLV 
VSV-G NFκB biosensor 
Integration-defective lentivirus vector biosensor was injected at birth via an intracranial administration. 
The mice were imaged continually. A fold change was calculated by comparing the medians from days 3 
to 7 to the raw values obtained. This is shown in panel A. In panel B the fold change after the LPS 
administration is further emphasised. The mice which received VSV-G IDLV NFκB biosensor showed to 
respond to LPS.  
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Figure 49 - Fold change of luciferase expression from mice which have received either integrating or 
IDLV VSV-G NFκB biosensor. 
Mice received the biosensor at birth via an intracranial administration and were imaged continually. The 
key represents the biosensors used in this experiment. A fold change was calculated by comparing the 
medians from days 3 to 7 to the raw values obtained. The mice which received VSV-G IDLV NFκB and VSV-
G NFκB biosensor showed to respond to LPS However, there was a significant difference between the two 
groups responding to LPS, P = 0.025. Standard deviation error bars are also included for each point in the 
graph.  
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9 Results VII - Somatic transgenesis using AAV biosensors 
 
As I have shown within this thesis, lentivirus biosensor vectors were not able to achieve 
widespread transduction within the CNS (3.2 “Validating neonatal intracranial injections of 
lentivirus vector” on page 61). Also I have shown that non integrating lentiviral vectors can 
also achieve somatic transgenesis. I therefore decided to move on to the AAV viral vector as 
studies have shown that these vectors are able to achieve a wide spread of transgene through 
intracranial injections (Inagaki et al. 2008; Klein et al. 2008). Mice received an intracranial 
injection of AAV8-CMV-GFP (1 x 1013 viral particles/mL) at birth. The brain tissues were 
harvested and immunohistochemistry for GFP was detected. The results revealed widespread 
GFP expression within the brain, extending from the olfactory bulb to the cerebellum, shown 
in Figure 50. The GFP expression was not restricted to the injection site.  
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Figure 50 - Spread of AAV8-CMV-GFP viral vector within the CNS 
After a neonatal intracranial injection of AAV8-CMV-GFP the GFP expression was present within the 
olfactory bulbs (A), frontal cortex (B), hippocampus (C) and the cerebellum (D). The spread of GFP 
expression was distributed within both hemispheres. The brain sections are taken at 5x magnification 
and the close up images are taken at x40 magnifications.  
Results VII - Somatic transgenesis using AAV biosensors | Page 133 
I hypothesised that the AAV8 NFκB biosensor would achieve widespread CNS transgene 
expression after neonatal intracranial injections.  
A sequence containing the following elements was assembled; pAAV-Gateway-luciferase-2A-
GFA-WPRE-PolyA (Section 11.5 “Sequence of pAAV-Gateway-luciferase-2A-GFA-WPRE-
PolyA” on page 159). This was synthesised by Aldevron (North Dakota, USA). I used Gateway 
recombination  (Section 2.2 “Gateway cloning” on page 37) to incorporate an NFκB response 
element producing the following plasmid; pAAV-NFκB-luciferase-2A-GFP-WPRE-PolyA (for 
sequence see section 11.6 “Sequence of pAAV-NFκB-luciferase-2A-GFA-WPRE-PolyA” on page 
163) . From this an AAV8 vector was generated (Ms. N. Martin Palomar, King’s College London, 
UK).  
To validate the AAV8 NFκB biosensor, the vector was administered to two adult males and 
two adult female mice at the age of 7 weeks, by an intraperitoneal administration (1 x 1012 
genome copies per mL). The luciferase expression was confined to the liver of the male 
injected mice and overall expression was 4 logs higher compared to the female mice. After 
receiving LPS the male mice showed a large up regulation of a ~200 fold to LPS 48 hours after 
injection (Figure 51).  
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Following validation of the AAV8 NFκB biosensor, the vector was administered to new-born 
neonatal mice via intracranial or intravenous routes. As AAV8 has been shown to cross the 
BBB (Gray et al. 2010), we wanted to monitor the differential expression achieved from using 
both these routes of administration.  
Whole body bioluminescence conscious images of these two sets of mice were taken daily for 
18 days, after which they were imaged every other day. The results showed that the mice 
which received an intracranial administration showed a widespread luciferase expression, 
Figure 51 - Luciferase expression observed within male mice after receiving an adult intraperitoneal 
administration of AAV8 NFκB biosensor 
The two male mice received an intraperitoneal administration of AAV8 NFκB biosensor at 7 weeks of age. 
Whole body bioluminescence imaging was taken every other day after administration. Luciferase expression 
was specifically seen within the liver. The mice received LPS (25mg/mL) 39 days after receiving the biosensor. 
A fold change in bioluminecsence of ~200 was observed 48 hours after the administration of LPS.  
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shown in Figure 52. The results of the intravenous injected mice are shown in the appendices, 
Figure 54 on page 138.  
Both set of mice received an intraperitoneal administration of LPS at day 32 (shown by the 
red triangle in Figure 52). Upon receiving LPS there was a marked up regulation of luciferase 
expression under the control of a NFκB response element up to 48 hours post injection. 
However, as the expression levels before the administration of LPS were high, therefore there 
was no significant up regulation of luciferase post LPS, as shown by a 2-way ANOVA.  
The luciferase expression from the mice which received the AAV8 NFκB biosensor 
intracranially was compared to mice which received the lentiviral VSV-G NFκB biosensor.  The 
results showed that the luciferase expression from the AAV biosensor was 3-logs greater than 
the lentiviral biosensor over development, shown in Figure 53.  
To localise luciferase expression, I anaesthetised the mice and imaged them on their front 
and back. The intracranial injected mice showed luciferase expression within the brain and 
the spinal cord. Interestingly luciferase was also detected within the  mouth, sternum, paws 
and tail (Figure 54). The intravenous injected mice results are shown in the appendices, 
section 11.4 “Figures from the AAV8 NFκB biosensors” on page 157. revealed that the 
luciferase expression was originating from the mouth, paws, sternum, lower abdomen, the 
tail and the spinal cord.  
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Figure 52 - Whole body bioluminescence imaging of mice which have received an intracranial 
injection of AAV8 NFκB biosensor 
After intracranial injections of the AAV8 NFκB biosensor the mice underwent conscious whole body 
bioluminescence imaging over development shown in panel A and B. Panel A shows neonatal mice and 
panel B shows adult mice being imaged. They then received an intraperitoneal injection of LPS at day 32 
of development (shown by the red arrow on the two linear graphs).  
A B 
C 
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Figure 53 - Lentiviral biosensor vs. AAV biosensor in the brain 
The lentivirus biosensor used was VSV-G NFκB (Titre - 1 x 109 viral particles/mL) and the AAV biosensor was 
AAV8 NFκB (Titre - 1 x 1013 viral particles/mL). Both sets of biosensors were administered to mice at birth via 
intracranial injections. The luciferase expression was plotted in a log graph and the results showed that the 
AAV8 biosensor produced a far greater expression than the lentiviral biosensor as the AAV viral vector had 
4 logs greater titre. However, the expression profile from the AAV biosensor is much more stable than the 
lentivirus biosensor. In each group there was an n of 8 and the mean expression is presented for each 
biosensor used.  
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Figure 54 – Whole body bioluminescence imaging of intracranial injected mice  whilst under anaesthetics 
intracranial mice were anesthetised and imaged on their back and front to monitor the location of the 
luciferase expression. The mouse in the middle labelled C is a control which has not received the AAV 
biosensor. The luciferase expression in panel A was observed in the mouth, paws, sternum and tail. In panel 
B the expression was present within the brain and spinal cord. 
C C 
A B 
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10 Discussion 
10.1 Establishing somatic transgenesis within the CNS with integrating lentivirus 
vectors  
 
The spread of GFP expression varied from lentiviral vectors which contained the GFP reporter 
gene to the lentiviral vector which contained the luciferase reporter gene, a 2A bicistronic 
linker and a GFP. Both lentiviral vectors contained SFFV as a promoter driving the reporter 
constructs.  
The GFP expression was strongest within the olfactory bulb and distributed through the 
ventricles of the CNS with all three lentiviral vectors used (VSV-G; pCCL-SFFV-GFP, LTR1-SFFV-
GFP and pLNT-SFFV-luc-2A-GFP). This may be due to the lentiviral vectors transducing 
neuronal stem cells within the rostral migratory stream (Sun et al. 2010). This stream contains 
immature neurons and astrocytes. The GFP expression was much more widespread within 
the CNS with the use of a VSV-G pCCL-SFFV-GFP vector (Section 3.2 “Validating neonatal 
intracranial injections of lentivirus vector” on page 61). The transduction efficiency within the 
mouse CNS of the VSV-G pCCL-SFFV-GFP vector was further highlighted when compared to 
the VSV-G pLNT-SFFV-Luc-2A-GFP biosensor vector (Section 3.2.1 “Determining the spread of 
VSV-G pseudotyped pLNT-SFFV-Luc-2A-GFP within the neonatal mouse brain” on page 66).  
The GFP expression within the VSV-G pLNT-SFFV-Luc-2A-GFP transduced brains seemed to be 
less (Figure 17 on page 67) compared to the VSV-G pCCL-SFFV-GFP transduced brains. This 
may be a consequence of the presence of the 2A bicistronic linker. Chan and colleagues have 
shown that placing the GFP reporter gene downstream of an 2A bicistronic linker reduces 
levels of the expression (Chan et al. 2011). This may be due to a structural changes which 
prevent the ribosomal cleavage from occurring (Rothwell et al. 2010). Therefore, this could 
be tested by staining for luciferase fusion protein within these mice.  
Long term but declining  luciferase expression within the CNS was observed with the use of a 
SFFV and GFAP promoters, NFκB and STAT3 response elements (Section 3.3.1 “Establishing 
CNS somatic transgenesis with the use of different transcription binding elements and 
promoter biosensors” on page 71). This correlates with what has previously been shown by 
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my colleagues and I with the use of a VSV-G NFκB biosensor within the mouse liver, lung and 
brain  (Buckley et al. 2015).  
The mice which received the VSV-G and GP64 STAT3 biosensor demonstrated an up-
regulation of luciferase expression specifically at P10 of development, shown in Figure 21 and 
Figure 56. (Section 3.3.1 “Establishing CNS somatic transgenesis with the use of different 
transcription binding elements and promoter biosensors” on page 71). This is consistent with 
previous reports demonstrating upregulation of JAK-STAT pathway in the mouse brain due to 
the hormone leptin, which reduce food intake and boost energy within hypothalamic neurons 
which peaks around P10 of development (Frontini et al. 2008). 
The biosensors were further validated in vivo with the administration of LPS to mice which 
had received either the VSV-G or GP64 NFκB and STAT3 biosensors. Only the mice which had 
received the VSV-G NFκB biosensor responded to the administration of LPS. However, the 
response to LPS was modest, in comparison to that seen in the liver (Buckley et al. 2015). This 
might be explained by minimal LPS passage through the BBB (Banks & Robinson 2010). Both 
the STAT3 biosensors failed to respond to LPS, even though previous studies have shown that 
STAT3 transcription factor activity is increased in response to inflammation (Yu et al. 2013).  
To investigate whether an inflammatory response was induced in response to neonatal 
intracranial lentiviral vector injections immunohistochemistry was conducted for astrogliosis 
and reactive microglia on brain tissues. The results showed that there was no evidence of 
astrogliosis nor reactive microglia in the brains which received a neonatal intracranial 
injection of lentiviral vectors, in contrast the adult positive controls revealed staining for GFAP 
and CD68 around the injection site (Section 3.4 “Injection-associated inflammation” on page 
77). These results are consistent with what Rahim and colleagues had shown that intracranial 
adult Rat injections result in reactive microglia, specifically around the injection site (Rahim 
et al. 2009). The absence of an inflammatory response to neonatal intracranial injections to 
the mouse brain is possibly due to the low concentrations of injury-induced cytokines at early 
stages of development (Balasingam et al. 1994).  
 All the biosensors administered to the CNS showed an approximate 2 logs decline in 
luciferase expression after weaning (Section 3.3 “Establishing somatic transgenesis within the 
CNS with the use of integrating lentivirus” on page 68). In order to determine whether it was 
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the ossification of the skull which was preventing the bioluminescence from passing through, 
an ex vivo luciferase assay was conducted. However, the ex vivo luciferase assay correlated 
with the in vivo luciferase expression (shown in Figure 25 on page 80). Therefore, the decline 
in the luciferase expression over development could be due to silencing of the lentivirus 
vector. Previous work has shown that standard lentivirus vector which contain SFFV or an 
CMV promoter are prone to transcriptional silencing, however by incorporating a ubiquitously 
acting chromatin opening elements (UCOEs) consisting  of methylation free CpG islands into 
an lentivirus backbone enables the stable expression of transgenes (Zhang et al. 2007). 
However, having said that, loss of expression within the CNS was evident for all biosensors. 
Perhaps transcriptional silencing is not restricted to lentiviral vectors which contain a 
constitutive promoter but can occur with the incorporation of response elements and 
transcriptional binding elements. Therefore, future work would involve the incorporation of 
the UCOEs within the lentivirus backbone to investigate the silencing of the transgene over 
development.  
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10.2 Validating the HIE model in outbred CD1 mice and using the somatic 
transgenic technology within neurological disease models 
 
The HIE mouse model was established and validated within this project by using outbred CD1 
mice (Section 4.1 “Establishing the HIE model within outbred CD1 mice” on page 83). These 
results matched what was previously demonstrated by Sheldon et al. Three mouse strains 
and three F1 mixed strains had been monitored to investigate their susceptibility to hypoxic-
ischemia. The results revealed that the CD1 strain was most tolerant to hypoxic-ischemic 
insult. However, the mortality rate increased to 61% at 90 minutes (Sheldon et al. 1998). In 
this study the percentage of oxygen used was 8%, whereas in my experiments mice were 
exposed to 10% oxygen balanced with nitrogen as described by Hagberg (Hagberg et al. 2004).  
Somatic transgenic technology was applied to the HIE disease model. Somatic transgenic 
bioimaging provides the unique opportunity to image conscious mice, since the biosensor can 
be targeted to specific organs. During the hypoxic ischemic injury there are two phases of 
energy failure; the primary energy failure results in decreased oxygen and glucose which 
consequently reduces the levels of ATP which can result in cellular death (Allen & Brandon 
2011). Studies have shown that by exposure of primary mouse neuronal and astrocytic cells 
to isoflurane reduces neuronal axonal growth by 30% and partially inhibits astrocytes to 
support the neuronal growth (Ryu et al. 2014). However, other studies have also shown that 
isoflurane preconditions the brain and attenuates the neuronal loss within the cerebral cortex 
and the hippocampus in ischaemic rat brains (Zhao et al. 2007). Therefore, anesthetising the 
neonatal mice which have received HIE surgery for bioimaging risks changing the model and 
the neurological outcome. Hence, the mice were imaged consciously before and after surgery.  
When the somatic transgenic technology was introduced into the HIE mouse model, both 
pseudotypes of lentiviral vectors were used. The results were summarised in Table 1 on page 
104 and Table 2 on page 109. The results revealed that only the first GP64 NFκB and GP64 
SFFV experiment agreed with the original hypothesis, which was that the bioluminescence 24 
hours after surgery would significantly correlate with the weight of the HIE mice 7 days’ post-
surgery. Therefore, the potential to predict the extent of injury 24 hours after surgery with 
the use of somatic transgenic technology was ruled out. The use of the biosensors within a 
different neurological disease model, the type II Gaucher disease model revealed that the 
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VSV-G SFFV biosensor did not respond to the neurological pathology occurring within the 
heterozygote mice (4.3 “Type II Gaucher disease model” on page 110).  
These outcomes may be due to the two different pseudotyping of lentivirus vectors targeting 
a different subset of cells within the CNS which would not necessarily depict the extent of 
injury occurring within the HIE mouse model.  
A possible reason as to why the biosensors did not respond well to the CNS damage is that 
the biosensors were administered to the left hemisphere of the CNS whereas infarct caused 
by HIE targets the right hemisphere. As the lentiviral spread within the CNS is mainly situated 
around the injection site (section 3.2 “Validating neonatal intracranial injections of lentivirus 
vector” on page 61), the biosensors are expressing luciferase on the undamaged hemisphere, 
which may not represent the extent of damage occurring within the CNS. This may be 
overcome by administering the biosensors bilaterally or within the right hemisphere or by 
using AAV.  
Studies have shown that constitutive high NFκB activity was present within specific regions of 
the mouse brain and the spinal cord (Schmidt-Ullrich et al. 1996). Therefore, a second 
possibility as to why the NFκB biosensors did not respond to damage is that the NFκB 
expression may be saturated and thus an addition of an agonist will not cause a further rise 
in NFκB activation.  
There also a third possible explanation. To detect the luciferase expression, both the 
substrate luciferin and ATP are required. During HIE as the tissue energy reserves start to 
deplete and the cells undergo apoptosis, these events are highly dependent on the lack of 
high energy phosphates, ATP (Thornton & Hagberg 2015). The ATP levels do return back to 
baseline, however a second round of energy depletion occurs which results in further decline 
in ATP and the cell eventually undergoes apoptosis (Thornton et al. 2012). Due to cell loss and 
eventually tissue loss, this may account for the amount of ATP available to generate a 
luciferase reaction. Therefore, this may explain why the biosensors did not respond to the 
CNS disease as it may mean that the less the luciferase expression the more the damaged 
occurring within the CNS. Historically firefly luciferase has been used to determine ATP 
concentrations (Lyman & DeVincenzo 1967). An alternative which might overcome this issue 
is to use another reporter transgene NanoLuc luciferase, which becomes reactive with the 
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addition of its substrate fumirazine, crucially does not depend on ATP (Schaub et al. 2015). 
However, this substrate needs to be administered intravenously, in order to detect the 
NanoLuc luciferase expression.  
The use of somatic transgenic technology within the HIE mouse model was not a reliable way 
of predicting long term injury. Repeated experiments generated inconsistent results.  
However, when the somatic transgenic technology was applied to a liver fibrosis mouse 
model, with the use of a VSV-G GFAP biosensor we observed a significant up-regulation of 
luciferase expression between the sham controls and the surgically induced mice (Figure 43 
on page 114). GFAP has been shown to be expressed within hepatic stellate cells and also 
been shown to be present within hepatic stellate cells derived myofibroblasts (Cassiman et 
al. 2002). Previous work conducted on a chemical induced liver cirrhosis rat model has shown 
that there was an increase in GFAP expression and showed an involvement in newly formed 
bile ductules (Tennakoon et al. 2015). Other groups have shown that hepatic myofibroblasts 
may be derived from the stem cell lineage (Tennakoon et al. 2013). Therefore, this suggests 
that an increase in luciferase expression, driven by a GFAP truncated promoter 72 hours after 
the bile duct ligation maybe due to the GFAP positive hepatic stellate cells and myofibroblasts 
involvement in the formation of bile ductules after the induction of liver fibrosis.  
The assumption that GP64 lentiviral vector targets GFAP positive astrocytes was further 
investigated by conducting fluorescent immunohistochemistry staining on brain tissues which 
had received an intracranial injection of either GP64 or VSV-G SFFV biosensor at birth. GFP 
was co-stained with antibodies directed against markers of astrocytes, microglia and neurons. 
The results showed that GP64 pseudotyped SFFV biosensor was targeting only a few 
protoplasmic and fibrotic astrocyte cells (Figure 44 on page 117) but majority of cells targeted 
could not be identified. This is not consistent with previous work where by GP64 pseudotyped 
lentivirus vector has shown to target astrocytic cells (Rahim et al. 2009). However, this was 
an adult rat intracranial injection.  
VSV-G pseudotyped SFFV biosensor resulted in mainly neuronal expression, shown in Figure 
45 on page 119. The results observed with the VSV-G pseudotyped SFFV biosensor agree with 
what has been previously shown (Rahim et al. 2009). Watson et al. demonstrated that 
injection of VSV-G pseudotyped lentivirus vector to the neonatal ventricles resulted in the 
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transduction of ependymal cells lining the ventricles and the choroid plexus (Watson et al. 
2005). Another study demonstrated that administration of lentivirus vector via intrathecal 
injections to a neonatal mouse resulted in the transduction of the meninges (Fedorova et al. 
2006).  
To further understand the results from the fluorescent immunohistochemistry, I transfected 
primary mouse neuronal and glia cells with different biosensors and monitored their 
luciferase expression.  
The GP64 GFAP and STAT3 biosensors expressed luciferase significantly stronger within glia 
cells than in primary neuronal cell. However, the GP64 NFκB biosensor revealed the exact 
opposite results (Section 7.1 “Transduction of neuronal and glial cells with GP64 biosensors ” 
on page 121). The glial transduction agrees with the in vivo data which showed that the GP64 
pseudotyped lentivirus vector targets only a few astrocytic cells. However, with the GP64 
NFκB biosensor showed greater luciferase expression within neuronal cells than glial cells. 
This may agree with what has been previously shown that NFκB activity is detected in the 
developing mouse brain specifically within neurons (Schmidt-Ullrich et al. 1996). 
The VSV-G NFκB biosensor transduced the primary neuronal cells and produced a significant 
luciferase transgene expression compared to the transduced glia cells (Section 7.2 
“Transduction of neuronal cells with VSV-G NFκB biosensors ” on page 123). Again these 
results confirmed what was shown by the in vivo data (Section 6.2 “CNS targeted by VSV-G 
SFFV biosensor” on page 118).  
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10.3 Widespread somatic transgenesis achieved with the use of an AAV8-NFκB 
biosensor  
 
Lentivirus vectors achieves only limited spread in the CNS as demonstrated in the previous 
chapters (Section 3.2 “Validating neonatal intracranial injections of lentivirus vector” on page 
61).  
To achieve an extensive distribution of the transgenes an AAV vector would be best suited as 
previous work has shown that by administering AAV8 to the fetal mouse brain produces global 
gene delivery within the CNS (Rahim et al. 2012).  
Therefore, with the help of Ms. N. Martin Palomar from King’s College London we generated 
an AAV-NFκB biosensor, which was made into an AAV8 serotyped vector. To investigate 
whether the AAV vector was expressing the transgene, the vector was administered to adult 
male and female mice through intraperitoneal injection. We observed a liver specific 
transduction of the adult male mice, however the female injected mice failed to show liver 
specific transduction. This is consistent with a previous mouse study showing that AAV 
mediated gene expression was 7 fold higher in the livers of males than females (Davidoff et 
al. 2003).   
The AAV8-NFκB biosensor was administered to neonatal mice either intracranially or 
intravenously. Widespread transgenesis was achieved with both routes of administration, 
more so with the intravenous injected mice (Section 11.4 “Figures from the AAV8 NFκB 
biosensors” on page 157). Whereas previous studies show AAV8 serotype transduces many 
systemic tissues (Inagaki et al. 2008) through this route; we observed luciferase expression 
predominantly in the brain and spine after a neonatal intravenous administration. 
Intravenous neonatal injections of AAV8 viral vectors have shown to target the spinal cord 
(Foust et al. 2008), skeletal and cardiac muscles (Wang et al. 2005). The expression was 
predominately seen within the brain and the spinal cord, it may be a consequence of by NFκB 
being constitutively expressed within the developing mouse CNS (Schmidt-Ullrich et al. 1996).  
I also showed that administering the AAV biosensor to the brain, produced 3 logs greater 
luciferase expression that the lentiviral biosensor (Figure 53 - Lentiviral biosensor vs. AAV 
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biosensor in the brain” on page 137). This agrees with previous work that AAV8 shows an 
extensive global expression of transgenes within the CNS (Rahim et al. 2012).  
The reason behind administering the AAV8-NFκB biosensor intravenously was to produce a 
somatic transgenic mouse which would complement a germline transgenic mouse. Also it was 
because in the future we would like to place Lox-P Stop sites upstream of the reporter genes 
in the AAV biosensor which would allow us to switch on the expression when crossing the 
mice with specific Cre lines.  
In order to determine which organs have been specifically targeted by the AAV8-NFκB 
biosensor, tissues from the injected mice would have to be collected for 
immunohistochemistry to determine GFP reporter gene expression. qPCR would also need to 
be carried out to determine vector copy number within specific organs.  
 
To conclude I have established somatic transgenesis with in the mouse CNS using integrating 
and non-integrating lentivirus vectors. The somatic transgenesis was further expanded with 
its spread of luciferase with the use of an AAV viral vectors. This generated a light emitting 
animal which complimented germline transgenic strains. I also established and set up a novel 
HIE disease model with the use of outbred CD1 strain.  
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11 Appendices  
11.1 Reagents and buffers  
 
11.1.1  Bacterial transformations and maintenance of E.coli  
  
Ampicillin Life Technologies, Glasgow, UK 
ccdB chemically competent E.coli cells Life Technologies 
Luria-Bertani agar  Life Technologies 
Luria-Bertani Broth Life Technologies 
One Shot Stbl3TM   Life Technologies 
Qiagen Maxi-prep kit Qiagen, Manchester, UK 
Qiagen Mini-prep kit Qiagen 
SOC medium Life Technologies 
11.1.2 Gateway Cloning 
 
Phusion High-Fidelity DNA Polymerase New England Biolabs, Ipswich, UK 
1kb plus ladder Life Technologies 
Agarose Life Technologies 
Bovine Serum Albumin Promega, Southampton, UK 
Clonase Life Technologies 
Dimethylsulfoxide (DMSO) Sigma Aldrich, Dorset, UK 
dNTP VWR, Leicestershire, UK 
Protinease K Life Technologies 
Qiagen gel extraction kit Qiagen 
Quick ligase kit New England Biolabs 
Restriction enzymes New England Biolabs 
Safeview NBS Biologicals, Cambridgeshire, UK 
TE Buffer  Life Technologies 
   
Appendices | Page 150 
11.1.3 Cell culture 
 
 
 
 
0.05% Trypsin-EDTA Life Technologies 
1x Phosphate buffered Saline Life Technologies 
DMEM Life Technologies 
Fetal Calf Serum Life Technologies 
 
11.1.4 Virus Production  
 
Isopropanol VWR 
10% Acrylamide gel Life Technologies 
2x LaemLli buffer Sigma Aldrich 
50KDa Polyethyleneimine (PEI) Sigma Aldrich 
50x MOPS buffer Life Technologies 
Benzonase Life Technologies 
Ethanol VWR 
Gel Red Biotium, Cambridge, UK 
Glycine Sigma Aldrich 
Hyperladder 1 New England Biolabs 
Magnesium Sulphate Sigma Aldrich 
Optimem Life Technologies 
p24 assay kit Zeptometric Corporation, New York, USA 
PEI (AAV) Polyscience,  Northampton, UK 
Protein ladder broad range New England Biolabs 
Sodium dexycholate VWR 
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11.1.5 In vivo experiments 
 
Isoflurane                                                                                                  Abbott Laboratories, London, UK 
D-Luciferin (Potassium salt) (LUCK-1G-OPT2) Gold Biotechnology Inc, St Louis, USA 
Hydrochloric acid Fisher chemical, Loughborough, UK 
Lipopolysaccharides Life Technologies 
Paraformaldehyde  Sigma Aldrich 
Sodium Azide VWR 
Sodium Chloride Sigma Aldrich 
Sucrose Sigma Aldrich 
 
11.1.6 Immunohistochemistry 
 
30% H2O2 Sigma Aldrich 
3,3'-Diaminobenzidine (DAB) Sigma Aldrich 
Anti-Glial Fibrillary Acidic Protein Antibody Merck Millipore, Hertfordshire, UK 
Chicken anit-GFP Aves labs, Oregon, USA 
DAPI Invitrogen 
Glacial Acetic Acid Sigma Aldrich 
Goat anti-chicken alexa fluor 488 dye Invitrogen 
Goat anti-rabbit alexa fluor 568 dye Invitrogen 
Histoclear National Diagnostics, Yorkshire, UK 
Mouse anti-Bax Abcam 
Mouse anti-NeuN Merck Millipore 
Mouse anti-X-linked antiapoptotic protein (XIAP)                BD Bioscience 
Nissl VWR 
Rabbit anti-GFP Antibody Abcam, Cambridge, UK 
Rabbit anti-Glutamine Synthase Abcam 
Rabbit anti-S100β Abcam 
Rat anti-mouse CD68  BioRad, Hertfordshire, UK 
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Secondary Antibody Vector Laboratories, Cambridge, UK 
Serum Vector Laboratories 
Triton X-100 Sigma Aldrich 
Vectastain Vector Laboratories 
Xylene VWR 
  
  
 
  
11.1.7 In vitro experiments  
  
Poly-D-lysin hyrdobromide  (PDL) Sigma 
Laminin Sigma 
Hanks Balanced Salt Solution Life Technologies 
Neuronal Isolation Kit MACS Miltenyl Biotec, Surrey, UK 
Neurobasal media Life Technologies 
50x B27 Life Technologies 
100x Stretomycin Life Technologies 
200mM Glutamine Life Technologies 
5X Lysis buffer Promega 
Luciferase Promega 
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LB (Luria-Bertani) 
Broth 
1L: 10g NaCl, 5g Yeast extract, 10g tryptone peptone. 
Autoclave 
LB Agar 1L: 10g NaCl, 5g Yeast extract, 10g tryptone peptone, 15g bacto 
agar. Autoclave. 
50 x TAE 1L: 242g Trisamine (Tris), 57.1 mL Glacial Acetic Acid, 100mL 0.5M 
EDTA 
5x DNA loading dye 
(Orange G) 
25mL: 6.75g Ficoll (15%), 0.25g Orange G, up to 25mL with dH20 
TD buffer 1L: 8.18g NaCl, 372.8mg KCl, 95.26mg K2HPO4, 333.23mg MgCl2, 
3.03g Tris; pH 7.5. Autoclave 
MOPS buffer 1L: 50mL 20x MOPS buffer in 1L dH20 
Coomassie blue dye 1L: 500mL Methanol, 400mL dH20, 100mL Acetic acid, 2.5g 
Coomassie Brilliant blue R-250  
Destain solution  1L: 250mL Methanol, 680mL dH20, 70mL Acetic acid 
50x Alkaline 
Electrophoresis 
buffer 
1L: 100g NaOH, 14.62g EDTA 
Alkaline sample 
loading buffer 
350µl: 200µl 20% Glycerol, 80µl 50x Alkaline electrophoresis buffer, 
60µl of 20% SDS and dip pipette tip in Xylene Cyanol powder and 
mix in solution 
4x Gelred 1L: 1 gel volume solution in to 5.8g NaCl; 20mL 5M NaCl of dH20 
4% 
Paraformaldehyde 
(PFA) 
1L: 40g PFA in 1L 1x Phosphate-buffered saline (PBS) 
30% Sucrose 1L: 300g Sucrose in 1L 1x PBS 
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10x Tris-buferred 
Saline (TBS) 
1L: 24g Trisamine (Tris), 88g NaCl and 34mL Hydrochloric acid; pH 
7.6 
TBSAF 1L: 700mL 1x TBS, 3.5mL 10% Sodium Azide, 300mL Ethlyene Glycol 
and 150g Sucrose 
TBST 1L: 0.3% of Triton X-100 in 1x TBS 
0.5M Phosphate 
buffer (PB) 
1L: 20g NaOH, 71g NaH2PO4 in 1L ddH20, pH adjusted to 7.4 with 
H3PO4 
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11.2 Transduced primary neuronal culture with VSV-G SFFV biosensor 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 55 - GFP expression observed from primary neuronal cells transfected with VSV-
G SFFV lentivirus vector 
Primary neuronal cells were transfected with VSV-G SFFV virus (titre – 1 x 107 viral 
particles/mL).  GFP expression was detected at 48 hours and 72 hours post transfection. 
There was greater number of cells which were GFP positive 72 hours after transfection 
than 48 hours.  
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11.3 Fold change in bioluminescence showing peak at P10 with STAT3 biosensors  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 56 - Fold change in luciferase expression for STAT3 biosensors 
Panel A shows the fold change of luciferase expression for each individual mouse (n=6 per 
biosensor). The mean fold changes are shown in panel B and an increase in luciferase expression 
is again shown at P10.  
A 
B 
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11.4 Figures from the AAV8 NFκB biosensors  
 
 
 
 
 
Figure 57 - Luciferase expression from mice which have received an intravenous administration of 
the AAV8 biosensor 
The mice received an intravenous administration of the AAV biosensor at birth and the mice were 
imaged consciously over development, shown in the top panel. The fold change of luciferase expression 
was quantified. The mice received an intraperitoneal injection of LPS and this is shown by the red arrow.  
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Figure 58 - Intravenous injected mice imaged under anaesthetics on their back and front 
Mice were anesthetised and imaged on their front and back. The luciferase expression was 
observed within the mouth, sternum, tail, paws, brain and spinal cord.  
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11.5 Sequence of pAAV-Gateway-luciferase-2A-GFA-WPRE-PolyA 
 
pAAV.GW.JDG.WPRE.SV40pA  8129bp 
 
ITR  - ITR to ITR 5508bp 
GW  - 1705bp 
JDG  - 2526bp 
WPRE  - 590bp 
SV40pA - 193bp 
AmpR 
 
CGGACCGAGCGGCCGCATATGCAGGAACCCCTAGTGATGGAGTTGGCCACTCCCTCTCTGCGCGCT
CGCTCGCTCACTGAGGCCGGGCGACCAAAGGTCGCCCGACGCCCGGGCTTTGCCCGGGCGGCCTCA
GTGAGCGAGCGAGCGCGCAGCTGCCTGCAGGGGGAGCTCCGCCTGATGCGGTATTTTCTCCTTACG
CATCTGTGCGGTATTTCACACCGCATACGTCAAAGCAACCATAGTACGCGCCCTGTAGCGGCGCATT
AAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGC
TCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGG
GCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTTGGGTGATG
GTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTT
AATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGGCTATTCTTTTGATTTATA
AGGGATTTTGCCGATTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAAT
TTTAACAAAATATTAACGTTTACAATTTTATGGTGCACTCTCAGTACAATCTGCTCTGATGCCGCATA
GTTAAGCCAGCCCCGACACCCGCCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCA
TCCGCTTACAGACAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTCAGAGGTTTTCACCGTCATCAC
CGAAACGCGCGAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAAT
GGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCT
AAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAA
AGGACCTAGGAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTG
CCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCA
CGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAA
CGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGG
GCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACA
GAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGAT
AACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACA
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ACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACG
ACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAAC
TACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACT
TCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCT
CGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGG
GGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGC
ATTGGTAACTTCGAATGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTT
AATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTT
TCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCG
CGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAG
CTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTCCTTCTAGT
GTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCC
TGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTT
ACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAA
CGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGA
GAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCC
AGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTT
TGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCC
TGGCCTTTTGCTGGCCTTTTGCTCACAATGCATTGTCCTGCAGGCAGCTGCGCGCTCGCTCGCTCACT
GAGGCCGCCCGGGCAAAGCCCGGGCGTCGGGCGACCTTTGGTCGCCCGGCCTCAGTGAGCGAGCG
AGCGCGCAGAGAGGGAGTGGCCAACTCCATCACTAGGGGTTCCTGCGGCTAGCGCCGCACGCGTG
TGTCTAGAGCTGCAGGAATTCGATGGCGCGCCATCAAACAAGTTTGTACAAAAAAGCTGAACGAGA
AACGTAAAATGATATAAATATCAATATATTAAATTAGATTTTGCATAAAAAACAGACTACATAATACT
GTAAAACACAACATATCCAGTCACTATGGCGGCCGCATTAGGCACCCCAGGCTTTACACTTTATGCTT
CCGGCTCGTATAATGTGTGGATTTTGAGTTAGGATCCGTCGAGATTTTCAGGAGCTAAGGAAGCTAA
AATGGAGAAAAAAATCACTGGATATACCACCGTTGATATATCCCAATGGCATCGTAAAGAACATTTT
GAGGCATTTCAGTCAGTTGCTCAATGTACCTATAACCAGACCGTTCAGCTGGATATTACGGCCTTTTT
AAAGACCGTAAAGAAAAATAAGCACAAGTTTTATCCGGCCTTTATTCACATTCTTGCCCGCCTGATGA
ATGCTCATCCGGAATTCCGTATGGCAATGAAAGACGGTGAGCTGGTGATATGGGATAGTGTTCACC
CTTGTTACACCGTTTTCCATGAGCAAACTGAAACGTTTTCATCGCTCTGGAGTGAATACCACGACGAT
TTCCGGCAGTTTCTACACATATATTCGCAAGATGTGGCGTGTTACGGTGAAAACCTGGCCTATTTCCC
TAAAGGGTTTATTGAGAATATGTTTTTCGTCTCAGCCAATCCCTGGGTGAGTTTCACCAGTTTTGATT
TAAACGTGGCCAATATGGACAACTTCTTCGCCCCCGTTTTCACCATGGGCAAATATTATACGCAAGG
CGACAAGGTGCTGATGCCGCTGGCGATTCAGGTTCATCATGCCGTTTGTGATGGCTTCCATGTCGGC
AGAATGCTTAATGAATTACAACAGTACTGCGATGAGTGGCAGGGCGGGGCGTAAACGCGTGGATCC
GGCTTACTAAAAGCCAGATAACAGTATGCGTATTTGCGCGCTGATTTTTGCGGTATAAGAATATATA
CTGATATGTATACCCGAAGTATGTCAAAAAGAGGTATGCTATGAAGCAGCGTATTACAGTGACAGTT
GACAGCGACAGCTATCAGTTGCTCAAGGCATATATGATGTCAATATCTCCGGTCTGGTAAGCACAAC
CATGCAGAATGAAGCCCGTCGTCTGCGTGCCGAACGCTGGAAAGCGGAAAATCAGGAAGGGATGG
CTGAGGTCGCCCGGTTTATTGAAATGAACGGCTCTTTTGCTGACGAGAACAGGGGCTGGTGAAATG
CAGTTTAAGGTTTACACCTATAAAAGAGAGAGCCGTTATCGTCTGTTTGTGGATGTACAGAGTGATA
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TTATTGACACGCCCGGGCGACGGATGGTGATCCCCCTGGCCAGTGCACGTCTGCTGTCAGATAAAGT
CTCCCGTGAACTTTACCCGGTGGTGCATATCGGGGATGAAAGCTGGCGCATGATGACCACCGATAT
GGCCAGTGTGCCGGTCTCCGTTATCGGGGAAGAAGTGGCTGATCTCAGCCACCGCGAAAATGACAT
CAAAAACGCCATTAACCTGATGTTCTGGGGAATATAAATGTCAGGCTCCCTTATACACAGCCAGTCT
GCAGGTCGACCATAGTGACTGGATATGTTGTGTTTTACAGTATTATGTAGTCTGTTTTTTATGCAAAA
TCTAATTTAATATATTGATATTTATATCATTTTACGTTTCTCGTTCAGCTTTCTTGTACAAAGTGGTGAT
TCGACGGTACCGCGGGCCCGGGATCCGCCACCATGGACTACAAAGACCATGACGGTGATTATAAAG
ATCATGACATCGATTACAAGGATGACGATGACAAGAGCGGCGGCGGCAGCATGGAGGACGCCAAG
AACATCAAGAAGGGACCAGCCCCCAGATACCCCCTGGAGGACGGCACAGCCGGCGAGCAGCTGCA
CAAGGCCATGAAGCGGTACGCCCAGGTGCCAGGCACCATCGCCTTCACCGACGCCCACATCGAGGT
GAACATCACCTACGCCGAGTACTTCGAGATGAGCGTGCGGCTGGCCGAGGCCATGAAGCGGTACG
GCCTGAACACCAACCACCGGATCGTGGTGTGCAGCGAGAACAGCCTGCAGTTCTTCATGCCCGTGCT
GGGAGCCCTGTTCATCGGCGTGGCCGTGGCCCCAGCCAACGACATCTACAACGAGCGGGAGCTGCT
GAACAGCATGAACATCAGCCAGCCCACCGTGGTGTTCGTGAGCAAGAAGGGCCTGCAGAAGATCCT
GAATGTGCAGAAGAAGCTGCCCATCATCCAGAAGATCATCATCATGGACAGCAAGACCGATTACCA
GGGCTTCCAGAGCATGTACACCTTCGTGACCAGCCACCTGCCCCCAGGCTTCAACGAGTACGACTTC
AAGCCCGAGAGCTTCGACCGGGACAAGACCATCGCCCTGATCATGAACAGCAGCGGCAGCACCGGC
CTGCCCAAGGGCGTGGCCCTGCCCCACCGGACCGCCTGCGTGCGGTTCAGCCACGCCAGAGACCCC
ATCTTCGGCAACCAGATCAAGCCCGACACCGCCATCCTGAGCGTGGTGCCCTTCCACCACGGCTTCG
GCATGTTCACCACCCTGGGCTACCTGATCTGCGGCTTCCGGGTGGTGCTGATGTACAGGTTCGAGGA
GGAGCTGTTCCTGCGGAGCCTGCAGGACTACAAGATCCAGAGCGCCCTGCTGGTGCCCACCCTGTTC
AGCTTCTTCGCCAAGAGCACCCTGATCGACAAGTACGACCTGAGCAACCTGCACGAGATCGCCTCTG
GCGGAGCCCCACTGAGCAAGGAGGTGGGCGAGGCCGTGGCCAAGCGGTTCCACCTGCCAGGCATC
CGGCAGGGCTACGGCCTGACCGAGACCACCAGCGCCATCCTGATCACCCCCGAGGGCGACGACAAG
CCCGGAGCCGTGGGCAAGGTGGTGCCCTTCTTCGAGGCCAAGGTGGTGGACCTGGACACCGGCAA
GACCCTGGGCGTGAACCAGAGAGGCGAGCTGTGCGTGAGAGGCCCCATGATCATGAGCGGCTACG
TGAACAACCCCGAGGCCACCAACGCCCTGATCGACAAGGACGGCTGGCTGCACAGCGGCGACATCG
CCTACTGGGACGAGGACGAGCACTTCTTCATCGTGGACCGGCTGAAGAGCCTGATCAAGTACAAGG
GCTACCAGGTGGCCCCAGCCGAGCTGGAGAGCATCCTGCTGCAGCACCCCAACATCCGGGACGCCG
GAGTGGCCGGACTGCCCGACGACGACGCCGGAGAGCTGCCAGCCGCCGTGGTGGTGCTGGAGCAC
GGCAAGACCATGACCGAGAAGGAGATCGTGGACTACGTGGCCAGCCAGGTGACCACCGCCAAGAA
GCTGAGAGGCGGCGTGGTGTTCGTGGACGAGGTGCCCAAGGGCCTGACCGGCAAGCTGGACGCCA
GAAAGATCCGGGAGATCCTGATCAAGGCCAAGAAGGGCGGCAAGATCCGCGCAGAGGGCCGGGG
CTCATTGCTGACCTGTGGAGATGTCGAGGAAAATCCCGGCCCCATGGTGAGCAAGGGCGAGGAGCT
GTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGGCGACGTAAACGGCCACAAGTTCAGCGT
GTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGCTGACCCTGAAGTTCATCTGCACCACCGG
CAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCTGACCTACGGCGTGCAGTGCTTCAGCCGC
TACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCCGCCATGCCCGAAGGCTACGTCCAGGAGC
GCACCATCTTCTTCAAGGACGACGGCAACTACAAGACCCGCGCCGAGGTGAAGTTCGAGGGCGACA
CCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTTCAAGGAGGACGGCAACATCCTGGGGCACA
AGCTGGAGTACAACTACAACAGCCACAACGTCTATATCATGGCCGACAAGCAGAAGAACGGCATCA
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AGGTGAACTTCAAGATCCGCCACAACATCGAGGACGGCAGCGTGCAGCTCGCCGACCACTACCAGC
AGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGCCCGACAACCACTACCTGAGCACCCAGTCCGC
CCTGAGCAAAGACCCCAACGAGAAGCGCGATCACATGGTCCTGCTGGAGTTCGTGACCGCCGCCGG
GATCACTCTCGGCATGGACGAGCTGTACAAGTAAGTCGAGAACGCACTAGTGTGCGGCCGCGACTC
TAGAGTCGACCTGCAGGCATGCAAGCTTGATATCAAGCTTATTTAATTAACGATAATCAACCTCTGG
ATTACAAAATTTGTGAAAGATTGACTGGTATTCTTAACTATGTTGCTCCTTTTACGCTATGTGGATAC
GCTGCTTTAATGCCTTTGTATCATGCTATTGCTTCCCGTATGGCTTTCATTTTCTCCTCCTTGTATAAAT
CCTGGTTGCTGTCTCTTTATGAGGAGTTGTGGCCCGTTGTCAGGCAACGTGGCGTGGTGTGCACTGT
GTTTGCTGACGCAACCCCCACTGGTTGGGGCATTGCCACCACCTGTCAGCTCCTTTCCGGGACTTTCG
CTTTCCCCCTCCCTATTGCCACGGCGGAACTCATCGCCGCCTGCCTTGCCCGCTGCTGGACAGGGGCT
CGGCTGTTGGGCACTGACAATTCCGTGGTGTTGTCGGGGAAATCATCGTCCTTTCCTTGGCTGCTCG
CCTGTGTTGCCACCTGGATTCTGCGCGGGACGTCCTTCTGCTACGTCCCTTCGGCCCTCAATCCAGCG
GACCTTCCTTCCCGCGGCCTGCTGCCGGCTCTGCGGCCTCTTCCGCGTCTTCGCCTTCGCCCTCAGAC
GAGTCGGATCTCCCTTTGGGCCGCCTCCCCGCATCTCGAGCGATACCGTCCTTAAGCAGACATGATA
AGATACATTGATGAGTTTGGACAAACCACAACTAGAATGCAGTGAAAAAAATGCTTTATTTGTGAAA
TTTGTGATGCTATTGCTTTATTTGTAACCATTATAAGCTGCAATAAACAAGTTAACAACAACAATTGC
ATTCATTTTATGTTTCAGGTTCAGGGGGAGGTGTGGGAGGTTTTTTAACCGGT 
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11.6 Sequence of pAAV-NFκB-luciferase-2A-GFA-WPRE-PolyA 
 
pAAV. NFkB.JDG.WPRE.SV40pA  6542bp 
 
ITR  - ITR to ITR 5508bp 
NFkB  - 118bp 
JDG  - 2526bp 
WPRE  - 590bp 
SV40pA - 193bp 
AmpR 
 
 
 
CGGACCGAGCGGCCGCATATGCAGGAACCCCTAGTGATGGAGTTGGCCACTCCCTCTCTGCGCGCT
CGCTCGCTCACTGAGGCCGGGCGACCAAAGGTCGCCCGACGCCCGGGCTTTGCCCGGGCGGCCTCA
GTGAGCGAGCGAGCGCGCAGCTGCCTGCAGGGGGAGCTCCGCCTGATGCGGTATTTTCTCCTTACG
CATCTGTGCGGTATTTCACACCGCATACGTCAAAGCAACCATAGTACGCGCCCTGTAGCGGCGCATT
AAGCGCGGCGGGTGTGGTGGTTACGCGCAGCGTGACCGCTACACTTGCCAGCGCCCTAGCGCCCGC
TCCTTTCGCTTTCTTCCCTTCCTTTCTCGCCACGTTCGCCGGCTTTCCCCGTCAAGCTCTAAATCGGGG
GCTCCCTTTAGGGTTCCGATTTAGTGCTTTACGGCACCTCGACCCCAAAAAACTTGATTTGGGTGATG
GTTCACGTAGTGGGCCATCGCCCTGATAGACGGTTTTTCGCCCTTTGACGTTGGAGTCCACGTTCTTT
AATAGTGGACTCTTGTTCCAAACTGGAACAACACTCAACCCTATCTCGGGCTATTCTTTTGATTTATA
AGGGATTTTGCCGATTTCGGCCTATTGGTTAAAAAATGAGCTGATTTAACAAAAATTTAACGCGAAT
TTTAACAAAATATTAACGTTTACAATTTTATGGTGCACTCTCAGTACAATCTGCTCTGATGCCGCATA
GTTAAGCCAGCCCCGACACCCGCCAACACCCGCTGACGCGCCCTGACGGGCTTGTCTGCTCCCGGCA
TCCGCTTACAGACAAGCTGTGACCGTCTCCGGGAGCTGCATGTGTCAGAGGTTTTCACCGTCATCAC
CGAAACGCGCGAGACGAAAGGGCCTCGTGATACGCCTATTTTTATAGGTTAATGTCATGATAATAAT
GGTTTCTTAGACGTCAGGTGGCACTTTTCGGGGAAATGTGCGCGGAACCCCTATTTGTTTATTTTTCT
AAATACATTCAAATATGTATCCGCTCATGAGACAATAACCCTGATAAATGCTTCAATAATATTGAAAA
AGGACCTAGGAGAGTATGAGTATTCAACATTTCCGTGTCGCCCTTATTCCCTTTTTTGCGGCATTTTG
CCTTCCTGTTTTTGCTCACCCAGAAACGCTGGTGAAAGTAAAAGATGCTGAAGATCAGTTGGGTGCA
CGAGTGGGTTACATCGAACTGGATCTCAACAGCGGTAAGATCCTTGAGAGTTTTCGCCCCGAAGAA
CGTTTTCCAATGATGAGCACTTTTAAAGTTCTGCTATGTGGCGCGGTATTATCCCGTATTGACGCCGG
GCAAGAGCAACTCGGTCGCCGCATACACTATTCTCAGAATGACTTGGTTGAGTACTCACCAGTCACA
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GAAAAGCATCTTACGGATGGCATGACAGTAAGAGAATTATGCAGTGCTGCCATAACCATGAGTGAT
AACACTGCGGCCAACTTACTTCTGACAACGATCGGAGGACCGAAGGAGCTAACCGCTTTTTTGCACA
ACATGGGGGATCATGTAACTCGCCTTGATCGTTGGGAACCGGAGCTGAATGAAGCCATACCAAACG
ACGAGCGTGACACCACGATGCCTGTAGCAATGGCAACAACGTTGCGCAAACTATTAACTGGCGAAC
TACTTACTCTAGCTTCCCGGCAACAATTAATAGACTGGATGGAGGCGGATAAAGTTGCAGGACCACT
TCTGCGCTCGGCCCTTCCGGCTGGCTGGTTTATTGCTGATAAATCTGGAGCCGGTGAGCGTGGGTCT
CGCGGTATCATTGCAGCACTGGGGCCAGATGGTAAGCCCTCCCGTATCGTAGTTATCTACACGACGG
GGAGTCAGGCAACTATGGATGAACGAAATAGACAGATCGCTGAGATAGGTGCCTCACTGATTAAGC
ATTGGTAACTTCGAATGTCAGACCAAGTTTACTCATATATACTTTAGATTGATTTAAAACTTCATTTTT
AATTTAAAAGGATCTAGGTGAAGATCCTTTTTGATAATCTCATGACCAAAATCCCTTAACGTGAGTTT
TCGTTCCACTGAGCGTCAGACCCCGTAGAAAAGATCAAAGGATCTTCTTGAGATCCTTTTTTTCTGCG
CGTAATCTGCTGCTTGCAAACAAAAAAACCACCGCTACCAGCGGTGGTTTGTTTGCCGGATCAAGAG
CTACCAACTCTTTTTCCGAAGGTAACTGGCTTCAGCAGAGCGCAGATACCAAATACTGTCCTTCTAGT
GTAGCCGTAGTTAGGCCACCACTTCAAGAACTCTGTAGCACCGCCTACATACCTCGCTCTGCTAATCC
TGTTACCAGTGGCTGCTGCCAGTGGCGATAAGTCGTGTCTTACCGGGTTGGACTCAAGACGATAGTT
ACCGGATAAGGCGCAGCGGTCGGGCTGAACGGGGGGTTCGTGCACACAGCCCAGCTTGGAGCGAA
CGACCTACACCGAACTGAGATACCTACAGCGTGAGCTATGAGAAAGCGCCACGCTTCCCGAAGGGA
GAAAGGCGGACAGGTATCCGGTAAGCGGCAGGGTCGGAACAGGAGAGCGCACGAGGGAGCTTCC
AGGGGGAAACGCCTGGTATCTTTATAGTCCTGTCGGGTTTCGCCACCTCTGACTTGAGCGTCGATTTT
TGTGATGCTCGTCAGGGGGGCGGAGCCTATGGAAAAACGCCAGCAACGCGGCCTTTTTACGGTTCC
TGGCCTTTTGCTGGCCTTTTGCTCACAATGCATTGTCCTGCAGGCAGCTGCGCGCTCGCTCGCTCACT
GAGGCCGCCCGGGCAAAGCCCGGGCGTCGGGCGACCTTTGGTCGCCCGGCCTCAGTGAGCGAGCG
AGCGCGCAGAGAGGGAGTGGCCAACTCCATCACTAGGGGTTCCTGCGGCTAGCGCCGCACGCGTG
TGTCTAGAGCTGCAGGAATTCGATGGCGCGCCATCAA GGGGACTTTCCACATAGGGGACTTTCCGT
CTGGGGACTTTCCGATCTGGGACTTTCCATCATGGGACTTTCCAGTCAGGGACTTTCCTTACGGGGA
CTTTCCCTTGCGGGGACTTTCCGATTCGACGGTACCGCGGGCCCGGGATCCGCCACCATGGACTACA
AAGACCATGACGGTGATTATAAAGATCATGACATCGATTACAAGGATGACGATGACAAGAGCGGCG
GCGGCAGCATGGAGGACGCCAAGAACATCAAGAAGGGACCAGCCCCCAGATACCCCCTGGAGGAC
GGCACAGCCGGCGAGCAGCTGCACAAGGCCATGAAGCGGTACGCCCAGGTGCCAGGCACCATCGC
CTTCACCGACGCCCACATCGAGGTGAACATCACCTACGCCGAGTACTTCGAGATGAGCGTGCGGCT
GGCCGAGGCCATGAAGCGGTACGGCCTGAACACCAACCACCGGATCGTGGTGTGCAGCGAGAACA
GCCTGCAGTTCTTCATGCCCGTGCTGGGAGCCCTGTTCATCGGCGTGGCCGTGGCCCCAGCCAACGA
CATCTACAACGAGCGGGAGCTGCTGAACAGCATGAACATCAGCCAGCCCACCGTGGTGTTCGTGAG
CAAGAAGGGCCTGCAGAAGATCCTGAATGTGCAGAAGAAGCTGCCCATCATCCAGAAGATCATCAT
CATGGACAGCAAGACCGATTACCAGGGCTTCCAGAGCATGTACACCTTCGTGACCAGCCACCTGCCC
CCAGGCTTCAACGAGTACGACTTCAAGCCCGAGAGCTTCGACCGGGACAAGACCATCGCCCTGATC
ATGAACAGCAGCGGCAGCACCGGCCTGCCCAAGGGCGTGGCCCTGCCCCACCGGACCGCCTGCGTG
CGGTTCAGCCACGCCAGAGACCCCATCTTCGGCAACCAGATCAAGCCCGACACCGCCATCCTGAGCG
TGGTGCCCTTCCACCACGGCTTCGGCATGTTCACCACCCTGGGCTACCTGATCTGCGGCTTCCGGGT
GGTGCTGATGTACAGGTTCGAGGAGGAGCTGTTCCTGCGGAGCCTGCAGGACTACAAGATCCAGA
GCGCCCTGCTGGTGCCCACCCTGTTCAGCTTCTTCGCCAAGAGCACCCTGATCGACAAGTACGACCT
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GAGCAACCTGCACGAGATCGCCTCTGGCGGAGCCCCACTGAGCAAGGAGGTGGGCGAGGCCGTGG
CCAAGCGGTTCCACCTGCCAGGCATCCGGCAGGGCTACGGCCTGACCGAGACCACCAGCGCCATCC
TGATCACCCCCGAGGGCGACGACAAGCCCGGAGCCGTGGGCAAGGTGGTGCCCTTCTTCGAGGCCA
AGGTGGTGGACCTGGACACCGGCAAGACCCTGGGCGTGAACCAGAGAGGCGAGCTGTGCGTGAG
AGGCCCCATGATCATGAGCGGCTACGTGAACAACCCCGAGGCCACCAACGCCCTGATCGACAAGGA
CGGCTGGCTGCACAGCGGCGACATCGCCTACTGGGACGAGGACGAGCACTTCTTCATCGTGGACCG
GCTGAAGAGCCTGATCAAGTACAAGGGCTACCAGGTGGCCCCAGCCGAGCTGGAGAGCATCCTGCT
GCAGCACCCCAACATCCGGGACGCCGGAGTGGCCGGACTGCCCGACGACGACGCCGGAGAGCTGC
CAGCCGCCGTGGTGGTGCTGGAGCACGGCAAGACCATGACCGAGAAGGAGATCGTGGACTACGTG
GCCAGCCAGGTGACCACCGCCAAGAAGCTGAGAGGCGGCGTGGTGTTCGTGGACGAGGTGCCCAA
GGGCCTGACCGGCAAGCTGGACGCCAGAAAGATCCGGGAGATCCTGATCAAGGCCAAGAAGGGCG
GCAAGATCCGCGCAGAGGGCCGGGGCTCATTGCTGACCTGTGGAGATGTCGAGGAAAATCCCGGC
CCCATGGTGAGCAAGGGCGAGGAGCTGTTCACCGGGGTGGTGCCCATCCTGGTCGAGCTGGACGG
CGACGTAAACGGCCACAAGTTCAGCGTGTCCGGCGAGGGCGAGGGCGATGCCACCTACGGCAAGC
TGACCCTGAAGTTCATCTGCACCACCGGCAAGCTGCCCGTGCCCTGGCCCACCCTCGTGACCACCCT
GACCTACGGCGTGCAGTGCTTCAGCCGCTACCCCGACCACATGAAGCAGCACGACTTCTTCAAGTCC
GCCATGCCCGAAGGCTACGTCCAGGAGCGCACCATCTTCTTCAAGGACGACGGCAACTACAAGACC
CGCGCCGAGGTGAAGTTCGAGGGCGACACCCTGGTGAACCGCATCGAGCTGAAGGGCATCGACTT
CAAGGAGGACGGCAACATCCTGGGGCACAAGCTGGAGTACAACTACAACAGCCACAACGTCTATAT
CATGGCCGACAAGCAGAAGAACGGCATCAAGGTGAACTTCAAGATCCGCCACAACATCGAGGACG
GCAGCGTGCAGCTCGCCGACCACTACCAGCAGAACACCCCCATCGGCGACGGCCCCGTGCTGCTGC
CCGACAACCACTACCTGAGCACCCAGTCCGCCCTGAGCAAAGACCCCAACGAGAAGCGCGATCACA
TGGTCCTGCTGGAGTTCGTGACCGCCGCCGGGATCACTCTCGGCATGGACGAGCTGTACAAGTAAG
TCGAGAACGCACTAGTGTGCGGCCGCGACTCTAGAGTCGACCTGCAGGCATGCAAGCTTGATATCA
AGCTTATTTAATTAACGATAATCAACCTCTGGATTACAAAATTTGTGAAAGATTGACTGGTATTCTTA
ACTATGTTGCTCCTTTTACGCTATGTGGATACGCTGCTTTAATGCCTTTGTATCATGCTATTGCTTCCC
GTATGGCTTTCATTTTCTCCTCCTTGTATAAATCCTGGTTGCTGTCTCTTTATGAGGAGTTGTGGCCCG
TTGTCAGGCAACGTGGCGTGGTGTGCACTGTGTTTGCTGACGCAACCCCCACTGGTTGGGGCATTGC
CACCACCTGTCAGCTCCTTTCCGGGACTTTCGCTTTCCCCCTCCCTATTGCCACGGCGGAACTCATCGC
CGCCTGCCTTGCCCGCTGCTGGACAGGGGCTCGGCTGTTGGGCACTGACAATTCCGTGGTGTTGTCG
GGGAAATCATCGTCCTTTCCTTGGCTGCTCGCCTGTGTTGCCACCTGGATTCTGCGCGGGACGTCCTT
CTGCTACGTCCCTTCGGCCCTCAATCCAGCGGACCTTCCTTCCCGCGGCCTGCTGCCGGCTCTGCGGC
CTCTTCCGCGTCTTCGCCTTCGCCCTCAGACGAGTCGGATCTCCCTTTGGGCCGCCTCCCCGCATCTC
GAGCGATACCGTCCTTAAGCAGACATGATAAGATACATTGATGAGTTTGGACAAACCACAACTAGA
ATGCAGTGAAAAAAATGCTTTATTTGTGAAATTTGTGATGCTATTGCTTTATTTGTAACCATTATAAG
CTGCAATAAACAAGTTAACAACAACAATTGCATTCATTTTATGTTTCAGGTTCAGGGGGAGGTGTGG
GAGGTTTTTTAACCGGT 
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